WO2021227500A1 - 生产l-缬氨酸的重组微生物及构建方法、应用 - Google Patents

生产l-缬氨酸的重组微生物及构建方法、应用 Download PDF

Info

Publication number
WO2021227500A1
WO2021227500A1 PCT/CN2020/137780 CN2020137780W WO2021227500A1 WO 2021227500 A1 WO2021227500 A1 WO 2021227500A1 CN 2020137780 W CN2020137780 W CN 2020137780W WO 2021227500 A1 WO2021227500 A1 WO 2021227500A1
Authority
WO
WIPO (PCT)
Prior art keywords
gene
valine
microorganism
dna fragment
homologous recombination
Prior art date
Application number
PCT/CN2020/137780
Other languages
English (en)
French (fr)
Inventor
张学礼
郭恒华
刘萍萍
张冬竹
唐金磊
韩成秀
唐思青
刘树蓬
马延和
Original Assignee
安徽华恒生物科技股份有限公司
中国科学院天津工业生物技术研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 安徽华恒生物科技股份有限公司, 中国科学院天津工业生物技术研究所 filed Critical 安徽华恒生物科技股份有限公司
Priority to EP20925003.4A priority Critical patent/EP3929297A4/en
Priority to US17/603,008 priority patent/US20230072835A1/en
Publication of WO2021227500A1 publication Critical patent/WO2021227500A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/08—Lysine; Diaminopimelic acid; Threonine; Valine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0016—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/01—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with NAD+ or NADP+ as acceptor (1.4.1)
    • C12Y104/01009—Leucine dehydrogenase (1.4.1.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/01—Oxidoreductases acting on NADH or NADPH (1.6) with NAD+ or NADP+ as acceptor (1.6.1)
    • C12Y106/01002—NAD(P)+ Transhydrogenase (AB-specific) (1.6.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01023—NAD+ kinase (2.7.1.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Definitions

  • the present invention relates to a method for constructing a recombinant microorganism for producing L-valine, the recombinant microorganism obtained by the constructing method, specifically recombinant Escherichia coli, and a method for producing L-valine through a fermentation method.
  • L-valine as one of the three major branched-chain amino acids (BCAA), is an essential amino acid, which cannot be synthesized in humans and animals and can only be obtained by supplementation from the outside world.
  • BCAA branched-chain amino acids
  • L-valine is widely used in the food and medicine fields, mainly including food additives, nutritional supplements and flavoring agents; widely used in the preparation of cosmetics, as well as antibiotics or herbicide precursors; in addition, with With the increasing demand for feed quality and ratio, L-valine will play an increasingly important role in the feed additive industry in the future, the demand will increase, and the future market has great potential. Microbial cells can directly synthesize L-valine, but a large number of intracellular feedback inhibition and other regulatory networks greatly limit the production capacity of wild cells.
  • L-valine is mainly produced through fermentation in the world.
  • the production strains used for fermentation are mostly derived by mutagenesis, and the starting strains mainly include Corynebacterium glutamicum, Brevibacterium flavum, Brevibacterium flavum and so on.
  • Chen Ning et al. used Brevibacterium flavum as the starting strain, used protoplast ultraviolet mutagenesis and combined with the strategy of DES chemical mutagenesis to screen and obtain a high-producing L-valine strain TV2564.
  • the strains obtained by traditional mutagenesis have strong randomness, and the genetic background is not clear, with many by-products, and it is not easy to obtain more high-yielding strains through further modification.
  • Xie Xixian and others integrated the Bacillus subtilis acetolactate synthase coding gene alsS, which relieved the feedback inhibition of L-valine on the synthesis pathway, and integrated the mutant gene spo TM of Escherichia coli ppGpp3'-pyrophosphohydrolase to enhance pyruvate.
  • the supply enhances the level of L-valine produced by shaking flask fermentation of the starting strain VHY03.
  • the publicly reported L-valine fermentation production is mostly achieved through aerobic or two-step fermentation.
  • the aerobic process requires air in the production process, which consumes a lot of energy; more importantly, a considerable part of the carbon source enters the tricarboxylic acid cycle (TCA) and is used for cell growth, causing the conversion rate to be lower than the theoretical maximum. Much lower.
  • TCA tricarboxylic acid cycle
  • the anaerobic process has the advantages of low energy consumption and high conversion rate. There is no need to vent air during the production process, which greatly saves energy consumption; the conversion rate of the product is usually close to the theoretical maximum.
  • the anaerobic fermentation of amino acid production was first realized in the process of alanine production.
  • the present invention found that the original enhancement of the activity of acetylhydroxyl isomerase and/or amino acid dehydrogenase can increase the yield and conversion rate of L-valine produced by Escherichia coli, and can realize the one-step anaerobic fermentation of L-valine acid.
  • the first aspect of the present invention provides a method for constructing a recombinant microorganism of L-valine.
  • the recombinant microorganism obtained by this method has a stable genetic background and a balanced L-valine reducing power, which is suitable for one step Method anaerobic fermentation.
  • the "enhancement" of enzyme activity refers to the increase of the intracellular activity of one or more enzymes in microorganisms that have the corresponding DNA encoding.
  • the enhancement of the activity can be achieved by any suitable method known in the art, for example, by Expression, including but not limited to increasing the copy number of the gene or allele, modifying the nucleotide sequence guiding or controlling gene expression, using a strong promoter or using protein activity or concentration is generally 10% higher than the initial microbial level- 500%.
  • the acetohydroxy acid isoreductase gene or/and the amino acid dehydrogenase gene is introduced into the microorganism, so that the enzyme activity is enhanced.
  • the acetohydroxy acid reductase gene and amino acid dehydrogenase gene introduced in the present invention are foreign to the introduced microorganism.
  • the acetohydroxy acid reductase gene and amino acid dehydrogenase gene may be corresponding genes from any microorganism such as Lactococcus, Bacillus and the like.
  • the acetohydroxy acid isoreductase gene and/or amino acid dehydrogenase gene are NADH-dependent.
  • NADH acetohydroxy acid isoreductase gene and/or amino acid dehydrogenase gene can be selected to consume excess NADH under anaerobic conditions and solve the problem of reducing power balance during anaerobic fermentation.
  • the acetohydroxy acid isoreductase gene is ilvC or KARI; the amino acid dehydrogenase gene is a leucine dehydrogenase gene.
  • the acetohydroxy acid isoreductase gene is KARI
  • the leucine dehydrogenase gene is leuDH
  • the acetohydroxy acid isoreductase gene and amino acid dehydrogenase gene may be present in the microorganism in any suitable manner known in the art, for example, in the form of a plasmid, or in a form integrated into the genome.
  • the enzyme-encoding gene integrated into the genome is placed under the control of a suitable regulatory element.
  • the control element is selected from M1-46 artificial control element, M1-93 artificial control element or RBS5 artificial control element;
  • the M1-46 artificial regulatory element regulates the ilvC gene.
  • the M1-93 artificial regulatory element regulates the leuDH gene
  • the RBS5 artificial regulatory element regulates the KARI gene.
  • the present invention also includes modifying one or more of the following enzyme genes of the above-mentioned recombinant microorganism as follows to reduce or inactivate the activity of these enzymes.
  • gene knockout can be performed in a manner known in the prior art, so that the activity of the enzyme is reduced or inactivated.
  • the knockout operation is aimed at the endogenous enzyme gene of the starting microorganism, so that the above-mentioned endogenous enzyme activity of the microorganism is reduced or inactivated.
  • the gene to replace these endogenous enzymes may be a gene to be expressed to be enhanced, such as the aforementioned ilvC gene, KARI gene or leuDH gene.
  • it further includes enhancing the activity of acetolactate synthase (AHAS) and/or dihydroxy acid dehydratase (ilvD) in the recombinant microorganism of the present invention.
  • AHAS acetolactate synthase
  • ilvD dihydroxy acid dehydratase
  • AHAS is selected from ilvBN, ilvGM or ilvIH, and the activity of at least one of them is enhanced.
  • the activity of AHAS is enhanced by releasing valine's feedback inhibition of ilvIH, for example, by mutating the ilvH gene to release valine's feedback inhibition of ilvIH.
  • AHAS III isozyme III
  • ilvIH operon which is composed of ilvI encoding the large subunit (catalytic subunit) and ilvH encoding the small subunit (control subunit).
  • AHASIII is feedback inhibition by L-valine.
  • the reported method can be used to mutate the ilvI gene, such as the amino acid substitution of ilvH 14Gly ⁇ Asp (Vyazmensky, M.
  • the activity of dihydroxy acid dehydratase (ilvD) in the recombinant microorganism of the present invention is enhanced, for example, by introducing the ilvD gene into the microorganism to enhance the activity of ilvD.
  • the operation is carried out in conjunction with the modification of item (2).
  • the operation is performed in conjunction with the modification of item (6).
  • the operation is performed in conjunction with the modification of the items (2) and (5).
  • the operation is carried out in combination with item (1) and item (3)-(6) modification.
  • the operation is performed in conjunction with the modification of items (1)-(6).
  • the endogenous mgsA gene of the microorganism is replaced with the ilvC gene to achieve the knockout of item (1).
  • the endogenous pflB gene of the microorganism is replaced with the ilvD gene, and/or the endogenous frd gene of the microorganism is replaced with the leuDH gene to achieve the knockout of item (6).
  • the KARI gene is substituted for the endogenous adhE gene of the microorganism to achieve the knockout of item (5).
  • the replacement can integrate the coding sequence of the gene to be inserted into the replaced gene coding sequence site in the microbial chromosome in a manner known to those skilled in the art, so that the original site gene coding sequence is integrated into the inserted gene The coding sequence is replaced.
  • the replacement of KARI, ilvC, ilvD and leuDH occurs simultaneously, wherein the ilvC gene can optionally be knocked out again.
  • the microorganism is Escherichia coli.
  • the microorganism is Escherichia coli ATCC 8739.
  • At least one regulatory element is used to regulate the genes of the aforementioned enzymes involved.
  • control element is selected from M1-46 artificial control element, M1-93 artificial control element or RBS5 artificial control element.
  • the M1-46 artificial regulatory element regulates the ilvC gene.
  • the M1-93 artificial regulatory element regulates the ilvD, leuDH, ilvBN and ilvGM genes.
  • the RBS5 artificial regulatory element regulates the KARI gene.
  • Regulatory elements can be inserted upstream of the ilvC gene by known genetic engineering methods.
  • the method includes, but is not limited to, inserting the sequence of the regulatory element into the upstream of the gene coding sequence of the target enzyme by means of gene recombination, for example, by means of homologous recombination, so as to enhance the intensity of expression of the target gene.
  • the gene encoding the enzyme and the regulatory element are integrated into the genome of the microorganism.
  • a plasmid containing the enzyme encoding gene and the regulatory element sequence is introduced into the microorganism.
  • the introduction, mutation or knockout of the target enzyme gene is accomplished by integrating into the genome of the microorganism.
  • the introduction, mutation or knockout of the enzyme gene is accomplished by the method of homologous recombination.
  • the introduction, mutation or knockout of the enzyme gene is accomplished by a two-step homologous recombination method.
  • Homologous recombination systems known in the art can be used, such as the E. coli RecA recombination system and the Red recombination system for homologous recombination to achieve the introduction, mutation or knockout of the target gene.
  • the two-step homologous recombination method to introduce, mutate or knock out the target gene includes the following steps (take E. coli as an example):
  • DNA fragment I Using pXZ-CS plasmid (Tan, et al., Appl Environment Microbiol, 2013, 79: 4838-4844) DNA as a template, use amplification primer 1 to amplify DNA fragment I, and use In the first step, homologous recombination;
  • DNA fragment II was amplified with the amplification primer 2. DNA fragment II is used for the second homologous recombination.
  • the second step of homologous recombination transform the DNA fragment II into the colonies selected in step (2); use the detection primer 2 to verify the transformed bacteria and select the colonies.
  • the second aspect of the present invention provides a recombinant microorganism for producing L-valine obtained by the above construction method, specifically a recombinant E. coli, which contains acetohydroxy acid isoreductase and/ Or the amino acid dehydrogenase gene,
  • E. coli ATCC 8739 is used as the starting strain to realize the coupling of intracellular cofactor NADH supply and cell growth through gene homologous recombination, so as to realize cell growth and L-valine production under anaerobic conditions. Coupling ( Figure 1).
  • the recombinant Escherichia coli obtained by the above-mentioned construction method undergoes further metabolic evolution, for example, through 50 generations, 70 generations, 80 generations, 90 generations, 100 generations, and 120 generations, a recombinant E. coli with high yield of L-valine is obtained.
  • a L-valine-producing recombinant Escherichia coli strain was obtained after 105 generations of metabolic evolution, which was deposited in the General Microbiology Center of the China Microbial Culture Collection Management Committee on March 6, 2020. It is located at No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing. The preservation number is CGMCC 19458, and the classification is named Escherichia coli.
  • the third aspect of the present invention is the application of the recombinant microorganism obtained by the above method in the production of L-valine.
  • the fourth aspect of the present invention is a method for fermentatively producing L-valine using the recombinant microorganism obtained by the above construction, which includes: (1) fermenting and cultivating the recombinant microorganism obtained by the construction; (2) separating and harvesting L-valine.
  • the fermentation culture is anaerobic fermentation culture.
  • the anaerobic fermentation includes the following steps:
  • Seed culture pick the clones on the plate and inoculate it into the seed culture medium, and culture it with shaking at 37°C to obtain the seed culture solution;
  • Fermentation culture inoculate the seed culture liquid in the fermentation medium, and ferment for 2 to 4 days at 37° C., 150 rpm, to obtain the fermentation liquid. Control the pH of the fermenter at 7.0. No gas is allowed to pass through the cultivation process.
  • the seed culture medium consists of the following components (the solvent is water):
  • Fermentation medium and seed medium have the same composition, the only difference is that the glucose concentration is 50g/L.
  • the present invention realizes the one-step anaerobic fermentation production of L-valine, reduces the production cost and improves the conversion rate.
  • the present invention preferably constructs a stable genetic L-valine production strain on the genome of the recombinant microorganism rather than in the form of a plasmid, without additional addition of antibiotics and inducers and other substances, and the production process is stable and easy to operate.
  • the recombinant Escherichia coli Sval065 constructed in the present invention is classified and named as Escherichia coli.
  • the biological material has been submitted for preservation on March 6, 2020.
  • the preservation unit The General Microbiology Center of the China Microbial Culture Collection Management Committee, The preservation address is No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing, Tel: 010-64807355, and the preservation number is CGMCC No. 19458.
  • Figure 2 Standards for the determination of L-valine by high performance liquid chromatography
  • Figure 5 Standards for the determination of L-valine by high performance liquid chromatography
  • strains and plasmids constructed in this study are shown in Table 1, and the primers used are shown in Table 2.
  • Example 1 Knockout of the mgsA gene encoding methylglyoxal synthase in ATCC 8739 strain
  • the primer mgsA-cs-up/mgsA-cs-down was used to amplify a 2719 bp DNA fragment I for the first step of homologous recombination.
  • the amplification system is: Phusion 5X buffer (New England Biolabs) 10 ⁇ l, dNTP (each dNTP each 10mM) 1 ⁇ l, DNA template 20ng, primer (10 ⁇ M) each 2 ⁇ l, Phusion High-Fidelity DNA polymerase (2.5U/ ⁇ l) 0.5 ⁇ l, 33.5 ⁇ l of distilled water, the total volume is 50 ⁇ l.
  • the amplification conditions are: 98°C pre-denaturation for 2 minutes (1 cycle); 98°C denaturation for 10 seconds, 56°C annealing for 10 seconds, 72°C extension for 2 minutes (30 cycles); 72°C extension for 10 minutes (1 cycle) .
  • the electrotransformation conditions are as follows: first prepare electrotransformation competent cells of Escherichia coli ATCC 8739 with pKD46 plasmid; place 50 ⁇ l of competent cells on ice, add 50ng DNA fragment I, place on ice for 2 minutes, and transfer to 0.2cm Bio -Rad shock cup. A MicroPulser (Bio-Rad company) electroporator was used, and the shock parameter was 2.5kv. After the electric shock, quickly transfer 1ml of LB medium to the electric shock cup, pipette 5 times and transfer to the test tube, incubate at 75 rpm and 30°C for 2 hours.
  • the primer XZ-mgsA-up/mgsA-del-down was used to amplify a 566bp DNA fragment II.
  • DNA fragment II is used for the second homologous recombination.
  • the amplification conditions and system are the same as those described in the first step.
  • the DNA fragment II was electroporated to the strain Sval001.
  • the electroporation conditions are as follows: first prepare the electrotransformation competent cells of Sval001 with pKD46 plasmid; place 50 ⁇ l of competent cells on ice, add 50ng DNA fragment II, place on ice for 2 minutes, and transfer to 0.2cm Bio-Rad electroshock Cup. A MicroPulser (Bio-Rad company) electroporator was used, and the shock parameter was 2.5kv. After the electric shock, quickly transfer 1ml of LB medium to the electric shock cup, pipette 5 times and transfer to the test tube, incubate at 30°C for 4 hours at 75 revolutions.
  • Example 2 Knockout of the gene encoding ldhA for lactate dehydrogenase
  • the first step using the pXZ-CS plasmid DNA as a template, using primers ldhA-cs-up/ldhA-cs-dwon to amplify a 2719 bp DNA fragment I for the first step of homologous recombination.
  • the amplification system and amplification conditions are the same as those described in Example 1. Electron transfer DNA fragment I to Sval002.
  • the DNA fragment I was used for the first homologous recombination: first, the pKD46 plasmid was transformed into E. coli Sval002 by electroporation, and then the DNA fragment I was electrotransformed into the E. coli Sval002 with pKD46.
  • the electroporation conditions and steps are the same as the first step method for mgsA gene knockout described in Example 1. Take 200 ⁇ l of bacterial solution and apply it on an LB plate containing ampicillin (final concentration of 100 ⁇ g/ml) and chloramphenicol (final concentration of 34 ⁇ g/ml). After incubating at 30°C overnight, select a single colony for PCR verification, using primers XZ-ldhA-up/XZ-ldhA-down was verified. The correct PCR product should be 3448bp. Pick a correct single colony and name it Sval003.
  • DNA fragment II was amplified with primers XZ-ldhA-up/ldhA-del-down. DNA fragment II is used for the second homologous recombination. The DNA fragment II was electrotransformed to the strain Sval003.
  • the electroporation conditions and steps are the same as the second step method for mgsA gene knockout described in Example 1.
  • Colony PCR was used to verify the clone.
  • the primers used were XZ-ldhA-up/XZ-ldhA-down, and the correct colony amplification product was a 829bp fragment.
  • a correct single colony was selected and named Sval004.
  • Example 3 Knockout of phosphoacetyltransferase encoding gene pta and acetate kinase encoding gene ackA
  • the primer ackA-cs-up/pta-cs-down was used to amplify a 2719 bp DNA fragment I for the first step of homologous recombination.
  • the amplification system and amplification conditions are the same as those described in Example 1. Electrotransfer DNA fragment I to Sval004.
  • the DNA fragment I was used for the first homologous recombination: first, the pKD46 plasmid was transformed into E. coli Sval004 by electroporation, and then the DNA fragment I was electrotransformed into the E. coli Sval004 with pKD46.
  • the electroporation conditions and steps are the same as the first step method for mgsA gene knockout described in Example 1. Take 200 ⁇ l of bacterial solution and apply it on an LB plate containing ampicillin (final concentration of 100 ⁇ g/ml) and chloramphenicol (final concentration of 34 ⁇ g/ml). After incubating at 30°C overnight, select a single colony for PCR verification, using primers XZ-ackA-up/XZ-pta-down for verification. The correct PCR product should be 3351bp. Pick a correct single colony and name it Sval005.
  • DNA fragment II was amplified with primers XZ-ackA-up/ackA-del-down. DNA fragment II is used for the second homologous recombination. The DNA fragment II was electrotransformed to the strain Sval005.
  • Example 4 Knockout of propionate kinase encoding gene tdcD and formate acetyltransferase encoding gene tdcE
  • DNA fragment I was used for the first homologous recombination: first, the pKD46 plasmid was transformed into E. coli Sval006 by electrotransformation, and then the DNA fragment I was electrotransformed into E. coli Sval006 with pKD46.
  • the electroporation conditions and steps are the same as the first step method for mgsA gene knockout described in Example 1. Take 200 ⁇ l of bacterial solution and apply it on an LB plate containing ampicillin (final concentration of 100 ⁇ g/ml) and chloramphenicol (final concentration of 34 ⁇ g/ml). After incubating at 30°C overnight, select a single colony for PCR verification, using primers XZ-tdcDE-up/XZ-tdcDE-down was verified. The correct PCR product should be 4380bp. Pick a correct single colony and name it Sval007.
  • the primer XZ-tdcDE-up/tdcDE-del-down was used to amplify a 895bp DNA fragment II.
  • DNA fragment II is used for the second homologous recombination.
  • the DNA fragment II was electroporated into the strain Sval007.
  • the electroporation conditions and steps are the same as the second step method for mgsA gene knockout described in Example 1.
  • Colony PCR was used to verify the clone.
  • the primers used were XZ-tdcDE-up/XZ-tdcDE-down, and the correct colony amplification product was a 1761bp fragment.
  • a correct single colony was selected and named Sval008.
  • the first step using pXZ-CS plasmid DNA as a template, using primers adhE-cs-up/adhE-cs-down to amplify a 2719bp DNA fragment I for the first step of homologous recombination.
  • the amplification system and amplification conditions are the same as those described in Example 1.
  • DNA fragment I was used for the first homologous recombination: first, the pKD46 plasmid was transformed into E. coli Sval008 by electrotransformation, and then the DNA fragment I was electrotransformed into E. coli Sval008 with pKD46.
  • the electroporation conditions and steps are the same as the first step method for mgsA gene knockout described in Example 1. Take 200 ⁇ l of bacterial solution and apply it on an LB plate containing ampicillin (final concentration of 100 ⁇ g/ml) and chloramphenicol (final concentration of 34 ⁇ g/ml). After incubating at 30°C overnight, select a single colony for PCR verification, using primers XZ-adhE-up/XZ-adhE-down was verified. The correct PCR product should be 3167bp. Pick a correct single colony and name it Sval009.
  • DNA fragment II was amplified with primers XZ-adhE-up/adhE-del-down. DNA fragment II is used for the second homologous recombination. The DNA fragment II was electrotransformed to the strain Sval009.
  • Example 6 Integration of acetohydroxy acid reductoisomerase encoding gene ilvC at the mgsA site of methylglyoxal synthase encoding gene
  • the acetohydroxy acid reductoisomerase encoding gene ilvC from Escherichia coli was integrated into the mgsA site of the methylglyoxal synthase encoding gene through a two-step homologous recombination method.
  • the specific steps include:
  • the cat-sacB fragment was integrated into the mgsA site of the Sval010 strain.
  • the PCR, integration, and verification of the cat-sacB fragment were exactly the same as the first step of mgsA gene knockout in Example 1, and the obtained clone was named Sval011.
  • DNA fragment II was amplified with the primer mgsA-ilvC-up/mgsA-ilvC-down. DNA fragment II is used for the second homologous recombination. The DNA fragment II was electroporated into the strain Sval011.
  • the electroporation conditions and steps are the same as the second step method for mgsA gene knockout described in Example 1.
  • Colony PCR was used to verify the clone.
  • the primers used were XZ-mgsA-up/XZ-mgsA-down, and the correct colony amplification product was a 2503bp fragment.
  • a correct single colony was selected and named Sval012.
  • the pXZ-CS plasmid DNA is used as a template, and the primer mgsA-Pcs-up/mgsA-Pcs-down is used to amplify a 2719 bp DNA fragment I for the first step of homologous recombination.
  • the amplification system and amplification conditions are the same as those described in Example 1. Electrotransfer DNA fragment I to Sval012.
  • the DNA fragment I was used for the first homologous recombination: first, the pKD46 plasmid was transformed into E. coli Sval012 by electrotransformation, and then the DNA fragment I was electrotransformed into the E. coli Sval012 with pKD46.
  • the electroporation conditions and steps are the same as the first step method for mgsA gene knockout described in Example 1. Take 200 ⁇ l of bacterial solution and apply it on an LB plate containing ampicillin (final concentration of 100 ⁇ g/ml) and chloramphenicol (final concentration of 34 ⁇ g/ml). After incubating at 30°C overnight, select a single colony for PCR verification, using primers XZ-mgsA-up/ilvC-YZ347-down for verification. The correct PCR product should be 3482bp. Pick a correct single colony and name it Sval013.
  • the second step is to use the genomic DNA of M1-46 (Lu, et al., Appl Microbiol Biotechnol, 2012, 93: 2455-2462) as a template, and use the primer mgsA-P46-up/ilvC-P46-down to amplify 188bp ⁇ DNA Fragment II.
  • DNA fragment II is used for the second homologous recombination.
  • the DNA fragment II was electroporated into the strain Sval013.
  • the electroporation conditions and steps are the same as the second step method for mgsA gene knockout described in Example 1.
  • Colony PCR was used to verify the clone.
  • the primer used was XZ-mgsA-up/ilvC-YZ347-down, and the correct colony amplification product was a 951bp fragment.
  • a correct single colony was selected and named Sval014.
  • Example 8 Integration of ilvD encoding dihydroxy acid dehydratase gene
  • the dihydroxy acid dehydratase encoding gene ilvD from Escherichia coli was integrated into the pflB site of the pyruvate formate lyase encoding gene by a two-step homologous recombination method and the pflB gene was replaced, that is, knocking out at the same time as ilvD was integrated.
  • the specific steps are as follows:
  • DNA fragment I was used for the first homologous recombination: first, the pKD46 plasmid was transformed into E. coli Sval014 by electrotransformation, and then the DNA fragment I was electrotransformed into E. coli Sval014 with pKD46.
  • the electroporation conditions and steps are the same as the first step method for mgsA gene knockout described in Example 1. Take 200 ⁇ l of bacterial solution and apply it on an LB plate containing ampicillin (final concentration of 100 ⁇ g/ml) and chloramphenicol (final concentration of 34 ⁇ g/ml). After incubating at 30°C overnight, select a single colony for PCR verification, using primers XZ-pflB-up600/XZ-pflB-down was verified. The correct PCR product should be 3675bp. Pick a correct single colony and name it Sval015.
  • the electroporation conditions and steps are the same as the second step method for mgsA gene knockout described in Example 1.
  • Colony PCR was used to verify the clone.
  • the primers used were XZ-pflB-up600/XZ-pflB-down, and the correct colony amplification product was a 2907bp fragment.
  • a correct single colony was selected and named Sval016.
  • Example 9 Expression regulation of ilvD encoding dihydroxy acid dehydratase gene
  • the first step using pXZ-CS plasmid DNA as a template, using primers pflB-Pcs-up/pflB-Pcs-down to amplify a 2719 bp DNA fragment I for the first step of homologous recombination.
  • the amplification system and amplification conditions are the same as those described in Example 1. Electrotransfer DNA fragment I to Sval016.
  • DNA fragment I was used for the first homologous recombination: first, the pKD46 plasmid was transformed into E. coli Sval016 by electrotransformation, and then the DNA fragment I was electrotransformed into E. coli Sval016 with pKD46.
  • the electroporation conditions and steps are the same as the first step method for mgsA gene knockout described in Example 1. Take 200 ⁇ l of bacterial solution and apply it on an LB plate containing ampicillin (final concentration of 100 ⁇ g/ml) and chloramphenicol (final concentration of 34 ⁇ g/ml). After incubating at 30°C overnight, select a single colony for PCR verification, using primers XZ-pflB-up600/ilvD-YZ496-down was verified. The correct PCR product should be 3756bp. Pick a correct single colony and name it Sval017.
  • the second step is to use the genomic DNA of M1-93 (Lu, et al., Appl Microbiol Biotechnol, 2012, 93: 2455-2462) as a template, and use primers pflB-Pro-up/ilvD-Pro-down to amplify 189bp ⁇ DNA Fragment II.
  • DNA fragment II is used for the second homologous recombination.
  • the DNA fragment II was electrotransformed to the strain Sval017.
  • the electroporation conditions and steps are the same as the second step method for mgsA gene knockout described in Example 1.
  • Colony PCR was used to verify the clone.
  • the primer used was XZ-pflB-up600/ilvD-YZ496-down, and the correct colony amplification product was a 1226bp fragment.
  • a correct single colony was selected and named Sval018.
  • the artificial regulatory element M1-93 is used to regulate the expression of the acetolactate synthase gene ilvBN through a two-step homologous recombination method. The specific steps are as follows:
  • the first step using pXZ-CS plasmid DNA as a template, use primers ilvB pro-catup/ilvB pro-catdown to amplify a 2719 bp DNA fragment I for the first step of homologous recombination.
  • the amplification system and amplification conditions are the same as those described in Example 1.
  • the DNA fragment I was used for the first homologous recombination: first, the pKD46 plasmid was transformed into E. coli Sval018 by electrotransformation, and then the DNA fragment I was electrotransformed into the E. coli Sval018 with pKD46.
  • the electroporation conditions and steps are the same as the first step method for mgsA gene knockout described in Example 1. Take 200 ⁇ l of bacterial solution and apply it on an LB plate containing ampicillin (final concentration of 100 ⁇ g/ml) and chloramphenicol (final concentration of 34 ⁇ g/ml). After incubating at 30°C overnight, select a single colony for PCR verification, using primers ilvB pro-YZup/ilvB pro-YZdown for verification. The correct PCR product should be 2996bp. Pick a correct single colony and name it Sval019.
  • the second step is to use the genomic DNA of M1-93 (Lu, et al., Appl Microbiol Biotechnol, 2012, 93: 2455-2462) as a template, and use primers ilvB pro-up/ilvB pro-down to amplify 188bp DNA Fragment II.
  • DNA fragment II is used for the second homologous recombination.
  • the DNA fragment II was electroporated into the strain Sval019.
  • the electroporation conditions and steps are the same as the second step method for mgsA gene knockout described in Example 1.
  • Colony PCR was used to verify the clone.
  • the primers used were ilvB pro-YZup/ilvB pro-YZdown, and the correct colony amplification product was a 465bp fragment.
  • a correct single colony was selected and named Sval020.
  • the artificial regulatory element M1-93 is used to regulate the expression of the acetolactate synthase gene ilvGM through a two-step homologous recombination method. The specific steps are as follows:
  • the primers ilvG pro-catup/ilvG pro-catdown are used to amplify a 2719 bp DNA fragment I for the first step of homologous recombination.
  • the amplification system and amplification conditions are the same as those described in Example 1.
  • DNA fragment I was used for the first homologous recombination: first, the pKD46 plasmid was transformed into E. coli Sval020 by electrotransformation, and then the DNA fragment I was electrotransformed into E. coli Sval020 with pKD46.
  • the electroporation conditions and steps are the same as the first step method for mgsA gene knockout described in Example 1. Take 200 ⁇ l of bacterial solution and apply it on an LB plate containing ampicillin (final concentration of 100 ⁇ g/ml) and chloramphenicol (final concentration of 34 ⁇ g/ml). After incubating at 30°C overnight, select a single colony for PCR verification, using primers ilvG pro-YZup/ilvG p-YZdown for verification. The correct PCR product should be 2993bp. Pick a correct single colony and name it Sval021.
  • the second step is to use the genomic DNA plasmid DNA of M1-93 (Lu, et al., Appl Microbiol Biotechnol, 2012, 93: 2455-2462) as a template, and use primers ilvG pro-up/ilvG pro-down to amplify 188bp ⁇ DNA Fragment II.
  • DNA fragment II is used for the second homologous recombination.
  • the DNA fragment II was electrotransformed to the strain Sval021.
  • the electroporation conditions and steps are the same as the second step method for mgsA gene knockout described in Example 1.
  • Colony PCR was used to verify the clone.
  • the primers used were ilvG pro-YZup/ilvG p-YZdown, and the correct colony amplification product was a 462 bp fragment.
  • a correct single colony was selected and named Sval022.
  • a two-step homologous recombination method is used to introduce mutations in the ilvH gene to release the feedback inhibition of L-valine.
  • the specific steps are as follows:
  • primers ilvH*-cat-up/ilvH*-cat-down are used to amplify a 2719 bp DNA fragment I for the first step of homologous recombination.
  • the amplification system and amplification conditions are the same as those described in Example 1.
  • the DNA fragment I was used for the first homologous recombination: first, the pKD46 plasmid was transformed into E. coli Sval022 by electrotransformation, and then the DNA fragment I was electrotransformed into the E. coli Sval022 with pKD46.
  • the electroporation conditions and steps are the same as the first step method for mgsA gene knockout described in Example 1. Take 200 ⁇ l of bacterial solution and apply it on an LB plate containing ampicillin (final concentration of 100 ⁇ g/ml) and chloramphenicol (final concentration of 34 ⁇ g/ml). After incubating at 30°C overnight, select a single colony for PCR verification, using primers ilvH*-mutYZ-up/ilvH*-mut-down for verification. The correct PCR product should be 3165bp. Pick a correct single colony and name it Sval023.
  • DNA fragment II was amplified with primers ilvH*-mut-up/ilvH*-mut-down. DNA fragment II is used for the second homologous recombination. The DNA fragment II was electrotransformed to the strain Sval023.
  • Example 13 Fermentation and production of L-valine using recombinant strain Sval024
  • the seed medium consists of the following components (the solvent is water):
  • Most of the fermentation medium is the same as the seed medium, except that the glucose concentration is 50g/L.
  • the anaerobic fermentation of Sval024 includes the following steps:
  • Seed culture Inoculate fresh clones on the LB plate into a test tube containing 4ml of seed culture medium, and cultivate overnight at 37°C with shaking at 250 rpm. Then, the culture was transferred to a 250 ml Erlenmeyer flask containing 30 ml of seed culture medium according to the inoculation amount of 2% (V/V), and the seed culture was obtained by shaking culture at 37° C. and 250 rpm for 12 hours for fermentation medium inoculation.
  • the neutralizer is 5M ammonia water to control the pH of the fermenter at 7.0. Do not pass any gas during the cultivation process.
  • Analytical method use Agilent (Agilent-1260) high performance liquid chromatograph to determine the components in the fermentation broth after 4 days of fermentation.
  • concentration of glucose and organic acid in the fermentation broth is determined using Biorad's Aminex HPX-87H organic acid analytical column.
  • Amino acid determination uses Sielc amino acid analysis column primesep 100 250 ⁇ 4.6mm.
  • the leuDH gene is a leuDH sequence derived from the Lysinibacillus sphaericus IFO 3525 strain according to literature reports (Ohshima, T.et.al, Properties of crystalline leucine dehydrogenase from Bacillus sphaericus. The Journal of biological chemistry 253, 5719-5725 (1978)) After codon optimization (optimized sequence is sequence 69), it is obtained through full gene synthesis. During synthesis, M1-93 artificial regulatory elements are added before the leuDH gene to initiate the expression of the leuDH gene, and inserted into the pUC57 vector to construct the plasmid pUC57-M1- 93-leuDH (Nanjing GenScript Biotechnology Co., Ltd.
  • the M1-93 artificial regulatory element and the leuDH gene were integrated into the frd site of the fumarate reductase encoding gene in the Sval024 strain through a two-step homologous recombination method, and the frd gene was replaced, that is, the frd gene was knocked out while leuDH was integrated .
  • the specific steps include:
  • the primer frd-cs-up/frd-cs-down was used to amplify a 2719 bp DNA fragment I for the first step of homologous recombination.
  • the amplification system and amplification conditions are the same as those described in Example 1.
  • DNA fragment I was used for the first homologous recombination: first, the pKD46 plasmid was transformed into E. coli Sval024 by electroporation, and then the DNA fragment I was electrotransformed into E. coli Sval024 with pKD46.
  • the electroporation conditions and steps are the same as the first step method for mgsA gene knockout described in Example 1. Take 200 ⁇ l of bacterial solution and apply it on an LB plate containing ampicillin (final concentration of 100 ⁇ g/ml) and chloramphenicol (final concentration of 34 ⁇ g/ml). After incubating at 30°C overnight, select a single colony for PCR verification, using primers XZ-frd-up/XZ-frd-down for verification. The correct PCR product should be 3493bp. Pick a correct single colony and name it Sval025.
  • primer frd-M93-up/frd-leuDH-down was used to amplify a 1283bp DNA fragment II.
  • DNA fragment II is used for the second homologous recombination.
  • the DNA fragment II was electroporated into the strain Sval025.
  • the electroporation conditions and steps are the same as the second step method for mgsA gene knockout described in Example 1.
  • Colony PCR was used to verify the clone.
  • the primers used were XZ-frd-up/XZ-frd-down, and the correct colony amplification product was a 2057bp fragment.
  • a correct single colony was selected and named Sval026.
  • Example 15 Fermentation and production of L-valine using recombinant strain Sval026
  • composition and formulation of the seed medium and the fermentation medium are the same as those described in Example 13.
  • the fermentation was carried out in a 500 mL fermentor, and the fermentation process and analysis process were the same as those of Sval024 described in Example 13.
  • Sval026 strain can produce 1.8g/L of L-valine (the L-valine peak corresponding to Figure 2) after fermentation for 4 days under anaerobic conditions, and the sugar-acid conversion rate is 0.56mol/mol .
  • Example 16 Integration of NADH-dependent acetohydroxy acid reductoisomerase encoding gene at adhE site of alcohol dehydrogenase gene
  • acetohydroxy acid reductoisomerase encoding gene kari is based on literature reports (Brinkmann-Chen, S., Cahn, JKB&Arnold, FHUncovering rare NADH-preferring ketol-acid reductoisomerases.
  • the kari sequence from Thermacetogenium phaeum strain is obtained through full gene synthesis after codon optimization (see sequence 70 for optimized sequence), and artificial regulation of RBS5 is added before the kari gene during synthesis
  • the element is used to initiate the expression of the kari gene, insert into the pUC57 vector, and construct the plasmid pUC57-RBS5-kari (Nanjing GenScript Biotechnology Co., Ltd. completes gene synthesis and vector construction).
  • the RBS5 artificial regulatory element and the kari gene were integrated into the adhE site of the alcohol dehydrogenase encoding gene in the Sval026 strain through a two-step homologous recombination method. The specific steps include:
  • the first step is to integrate the cat-sacB gene into the adhE gene site in Sval026, the fragments are obtained and purified, the first step is the integration of homologous recombination, and the verification is the same as the fragment used in the first step of homologous recombination in the adhE gene knock-out in Example 5. It was completely consistent with the method, and the obtained clone was named Sval061 (Table 1).
  • a 1188bp DNA fragment II was amplified with primers adhE-RBS5-up/adhE-kari-down. DNA fragment II is used for the second homologous recombination. The DNA fragment II was electroporated into the strain Sval061.
  • Example 17 Knockout of NADPH-dependent acetohydroxy acid reductoisomerase encoding gene at mgsA site
  • the first step is to integrate the cat-sacB gene into the mgsA site instead of the ilvC gene, obtain and purify the fragments, integrate the first step of homologous recombination, and verify that the fragments used in the first step of homologous recombination are knocked out by mgsA in Example 1. It was completely consistent with the method, and the obtained clone was named Sval063 (Table 1).
  • the second step is to replace the cat-sacB fragment with the mgsA knockout fragment to obtain the mgsA gene and ilvC gene knockout strain.
  • the fragments are obtained and purified, the second step is the integration of homologous recombination, and the verification is the same as the mgsA knockout in Example 1. Except that the fragments and methods used in the second step of homologous recombination are completely the same, the obtained clone is named Sval064.
  • Example 18 Fermentation and production of L-valine using recombinant strain Sval064
  • composition and formulation of the seed medium and the fermentation medium are the same as those described in Example 13.
  • the fermentation was carried out in a 500 mL fermentor, and the fermentation process and analysis process were the same as the fermentation process and analysis process of Sval024 described in Example 13.
  • Sval064 strain was fermented for 4 days under anaerobic conditions, and it was able to produce 2.0g/L of L-valine (the L-valine peak corresponding to Figure 2 appeared), and the sugar-acid conversion rate was 0.80mol/mol (Figure 3). ).
  • the evolutionary metabolism process uses a 500ml fermentor, and the fermentation medium is 250ml. Use 5M ammonia water as the neutralizer to control the pH of the fermenter at 7.0.
  • the composition and formulation of the fermentation medium used for evolutionary metabolism are the same as those described in Example 16 for the fermentation medium. Every 24 hours, the fermentation broth was transferred to a new fermentor to make the initial OD550 reach 0.1. After 105 generations of evolution, the strain Sval065 was obtained ( Figure 4). The Sval065 strain is deposited in the China Common Microorganism Collection Management Center (CGMCC) under the deposit number CGMCC 19458.
  • CGMCC Common Microorganism Collection Management Center
  • Example 20 The recombinant strain Sval065 was fermented to produce L-valine in a 500mL fermentor
  • composition and preparation of the seed medium are the same as those described in Example 13.
  • Fermentation is carried out in a 500mL fermentor, and the fermentation medium is 250ml.
  • the fermentation medium is basically the same as the seed medium. The difference is that the glucose concentration is 100g/L, and the neutralizer used is 5M ammonia, so that the pH of the fermenter is controlled at 7.0.
  • Example 21 The recombinant strain Sval065 was fermented to produce L-valine in a 5L fermentor
  • the composition, preparation and analysis method of the seed culture medium are the same as those described in Example 13.
  • the fermentation medium is basically the same as the seed medium, except that the glucose concentration is 140g/L.
  • the fermentation is carried out anaerobic in a 5L fermentor (Shanghai Baoxing, BIOTECH-5BG), including the following steps:
  • Seed culture 150ml seed culture medium in a 500ml Erlenmeyer flask, sterilized at 115°C for 15min. After cooling, the recombinant Escherichia coli Sval045 was inoculated into the seed culture medium at an inoculum of 1% (V/V), and cultivated at 37° C. and 100 rpm for 12 hours to obtain the seed liquid, which was used for the inoculation of the fermentation medium.
  • V/V inoculum of 1%

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

生产L-缬氨酸的重组微生物及构建方法、应用，通过向微生物中导入乙酰羟酸异构还原酶基因和/或氨基酸脱氢酶基因，同时增强乙酰羟基还原异构酶和氨基酸脱氢酶的活性，能够提高大肠杆菌生产L-缬氨酸的产量和转化率，且可实现一步法厌氧发酵L-缬氨酸。

Description

生产L-缬氨酸的重组微生物及构建方法、应用 技术领域
本发明涉及生产L-缬氨酸的重组微生物的构建方法，所述构建方法获得的重组微生物，具体是重组大肠杆菌，以及通过发酵法生产L-缬氨酸的方法。
背景技术
L-缬氨酸作为三大支链氨基酸(Branched-chain amino acid，BCAA)的一种，属于必需氨基酸，在人和动物中不能合成，只能通过从外界补充获得。目前，L-缬氨酸被广泛用于食品和医药领域，主要包括食品添加剂、营养增补液及风味剂等；广泛用于化妆品制备、以及用作抗生素或者除草剂前体等；另外，随着对饲料质量和配比需求的提高，在未来L-缬氨酸在饲料添加剂行业中的作用将越来越重要，需求量会越来越大，未来市场具有极大的潜力。微生物细胞可以直接合成L-缬氨酸，但胞内大量反馈抑制等调控网络极大地限制了野生细胞的生产能力。要想获得能够高效生产L-缬氨酸的发酵菌株，必须有效解除微生物细胞这些自我调节机制。目前，世界范围内L-缬氨酸主要通过发酵法生产获得。用于发酵的生产菌株多通过诱变而来，出发菌株主要包括谷氨酸棒杆菌、黄色短杆菌、黄色短杆菌等。陈宁等以黄色短杆菌为出发菌株，使用原生质体紫外诱变并结合DES化学诱变的策略，筛选获得了一株L-缬氨酸高产菌TV2564。但是，传统诱变获得的菌株具有很强的随机性，并且遗传背景不清晰，副产物多，并且不容易进一步通过改造获得更加高产的菌株。
近年来，随着合成生物学和代谢工程的迅速发展，通过遗传改造获得能够高效生产L-缬氨酸、遗传背景清晰、且易于培养的重组工程菌株应运而生并取得了很好的效果。Sang Yup Lee课题组2007年从大肠杆菌W3110出发，结合理性代谢工程、转录组分析和遗传改造、以及基因敲除等手段获得了一株能够生产L-缬氨酸的工程菌。该菌株在好氧条件下批式培养(batch culture)可以生产缬氨酸但其培养过程中需要持续通氧，且需添加L-异亮氨酸方能保证细胞正常生长。
谢希贤等整合枯草芽孢杆菌乙酰乳酸合酶的编码基因alsS，解除了L-缬氨酸对合成通路的反馈抑制，同时整合大肠杆菌ppGpp3’-焦磷酸水解酶的突变基因spo TM，增强了丙酮酸供应，增强了出发菌株VHY03的摇瓶发酵生产L-缬氨酸的水平。
目前公开报道的L-缬氨酸发酵生产多是通过好氧或者两步法发酵实现的。但是好氧工艺在生产过程中需要用空气，能耗很大；更关键的是，有相当一部分碳源进入三羧酸循环(TCA)从而被用于细胞生长，导致转化率比理论最大值要低很多。厌氧工艺和好氧相比，具有低能耗、高转化率的优点，生产过程中不需要通空气，大大节约能耗；产品的转化率通常接近理论最大值。氨基酸生产的厌氧发酵最早是在丙氨酸生产过程中实现的，目前其他氨基酸的生产暂未有纯厌氧发酵工艺的报道。此外，目前工程菌改造过程中关键基因的过表达都是通过在质粒上实现的，这就导致发酵过程中需要添加抗生素维持质粒存在，增加了生产成本并存 在在产业化生产中质粒丢失的风险。
因此，本领域仍需要提供稳定、高产、节能、简便的生产L-缬氨酸的重组微生物以及相应的L-缬氨酸的生产制备方法。
发明内容
本发明发现，原增强乙酰羟基还异构酶和/或氨基酸脱氢酶的活性，能够提高大肠杆菌生产L-缬氨酸的产量和转化率，且可实现一步法厌氧发酵L-缬氨酸。
本发明的第一个方面，是提供一种L-缬氨酸的重组微生物的构建方法，经该方法获得的重组微生物具有稳定遗传背景、且具备平衡的L-缬氨酸还原力，适宜一步法厌氧发酵。
在本申请中，酶的活性“增强”是指提高微生物中有相应的DNA编码的一种或多种酶的胞内活性，增强活性可以通过本领域已知的任何合适方法实现，例如通过过表达，包括但不限于提高所述基因或等位基因的拷贝数，修饰指导或控制基因表达的核苷酸序列，使用强启动子或使用蛋白质活性或浓度一般比起始微生物水平提高10％-500％。
在一个实施方式中，向微生物中导入乙酰羟酸异构还原酶基因或/和氨基酸脱氢酶基因，使得所述酶活性增强。
在一个实施方式中，本发明导入的乙酰羟基酸还原酶基因和氨基酸脱氢酶基因对于被导入的微生物而言是外源的。所述乙酰羟基酸还原酶基因和氨基酸脱氢酶基因可以是来自任何微生物例如乳球菌、芽孢杆菌等的相应基因。
在一个实施方式中，所述乙酰羟酸异构还原酶基因和/或氨基酸脱氢酶基因是NADH依赖型的。
厌氧条件下细胞产生的还原力类型大部分是NADH，为实现在厌氧条件下高效生产L-缬氨酸，须解决辅因子不平衡问题。本发明一个实施方式中选择NADH依赖型的乙酰羟酸异构还原酶基因和/或氨基酸脱氢酶基因能够使得厌氧条件下过剩的NADH得到消耗，解决厌氧发酵时还原力平衡的问题。
在一个实施方式中，所述乙酰羟酸异构还原酶基因是ilvC或KARI；所述氨基酸脱氢酶基因是亮氨酸脱氢酶基因。
在一个优选的实施方式中，所述乙酰羟酸异构还原酶基因是KARI，所述亮氨酸脱氢酶基因是leuDH。
所述乙酰羟酸异构还原酶基因和氨基酸脱氢酶基因可以以本领域已知的任何合适方式，例如以质粒形式，或者整合入基因组中的形式存在与所述微生物中。在一个实施方式中，所述整合入基因组中的酶编码基因置于合适的调控元件的控制下。
所述调控元件选自M1-46人工调控元件、M1-93人工调控元件或RBS5人工调控元件；
在一个实施方式中，M1-46人工调控元件调控ilvC基因。
在一个实施方式中，M1-93人工调控元件调控leuDH基因；
在一个实施方式中，RBS5人工调控元件调控KARI基因。
在一个实施方式中，本发明还包括对上述重组微生物的以下酶基因中的一种或几种进行如下改造，以使得这些酶的活性降低或失活。
(1)敲除甲基乙二醛合酶(mgsA)基因；
(2)敲除乳酸脱氢酶(ldhA)基因；
(3)敲除磷酸乙酰转移酶(pta)和/或乙酸激酶(ackA)基因；
(4)敲除丙酸激酶(tdcD)和/或甲酸乙酰转移酶(tdcE)基因；
(5)敲除醇脱氢酶(adhE)基因；
(6)敲除富马酸还原酶(frd)和/或丙酮酸甲酸裂解酶(pflB)基因。
本领域技术人员能够理解，可以用现有技术已知的方式进行基因敲除，使得所述酶的活性被降低或失活。所述的敲除操作针对的是出发微生物内源性的酶基因，使得微生物的上述内源性酶活性降低或失活。
还可以通过同源重组等基因工程的方式，以另一基因的编码序列取代上述(1)-(6)中所述酶基因的编码序列，从而使得微生物的上述内源性酶活性降低或失活。替代这些内源性酶的基因可以是待增强表达的基因，如上述的ilvC基因、KARI基因或leuDH基因。
在一个实施方式中，还包括增强本发明的重组微生物中的乙酰乳酸合成酶(AHAS)和/或二羟酸脱水酶(ilvD)的活性。
在一个优选地实施方式中，AHAS选自ilvBN、ilvGM或ilvIH，它们中至少一种酶的活性被增强。在一个优选地实施方式中，AHAS的活性通过解除缬氨酸对ilvIH的反馈抑制得到增强，例如通过突变ilvH基因解除缬氨酸对ilvIH的反馈抑制。
就涉及L-缬氨酸生物合成的乙酰羟酸合成酶而言，除了同功酶Ⅱ(这里也称为AHASⅡ)，还知道有同功酶Ⅲ(这里也称为AHASⅢ)。AHASⅢ由ilvIH操纵子编码，该操纵子由编码大亚基(催化亚基)的ilvI和编码小亚基(控制亚基)的ilvH组成。AHASⅢ受L-缬氨酸的反馈抑制。可采用已报道的方法突变ilvI基因，例如ilvH 14Gly→Asp的氨基酸取代(Vyazmensky,M.等，《生物化学》35:10339-10346(1996))和/或ilvH 17Ser→Phe(US6737255B2)；以及ilvH612(De Felice等，《细菌学杂志》120:1058-1067(1974))等。
在一个实施方式中，本发明的重组微生物中的二羟酸脱水酶(ilvD)的活性被增强，例如通过向微生物中导入ilvD基因增强ilvD的活性。
增强AHAS和/或二羟酸脱水酶(ilvD)的活性，任选地结合上述(1)-(6)任一项或几 项改造进行操作。
在一个实施方式中，结合第(2)项改造进行操作。
在一个实施方式中，结合第(6)项改造进行操作。
在一个实施方式中，结合第(2)项和第(5)项改造进行操作。
在一个实施方式中，结合第(1)项、第(3)-(6)项改造进行操作。
在一个实施方式中，结合第(1)-(6)项改造进行操作。
在一个实施方法中，任选地，以ilvC基因替换微生物内源性的mgsA基因来实现第(1)项敲除。
在一个实施方式中，以ilvD基因替换微生物内源性的pflB基因，和/或以leuDH基因替换微生物内源性的frd基因来实现第(6)项敲除。
在一个优选地实施方式中，以KARI基因替换微生物内源性的adhE基因来实现第(5)项敲除。
所述替换可以本领域技术人员已知的方式，将待插入的基因的编码序列整合到所述微生物染色体中被替换的基因编码序列位点，使得原位点基因编码序列被整合插入的基因的编码序列所取代。
优选地，KARI、ilvC、ilvD和leuDH的替换同时发生，其中ilvC基因可任选的被再次敲除。
在一个实施方式中，所述的微生物为大肠杆菌。
在一个实施方式中，所述的微生物为大肠杆菌ATCC 8739。
在一个实施方式中，使用至少一个调控元件调控上述涉及的酶的基因。
在一个实施方式中，所述调控元件选自M1-46人工调控元件、M1-93人工调控元件或RBS5人工调控元件。
在一个实施方式中，M1-46人工调控元件调控ilvC基因。
在一个实施方式中，M1-93人工调控元件调控ilvD、leuDH、ilvBN和ilvGM基因。
在一个实施方式中，RBS5人工调控元件调控KARI基因。
调控元件可通过已知的基因工程方法插入ilvC基因的上游。所述方法包括但不限于以基因重组的方式，例如以同源重组的方式调控元件的序列插入目标酶的基因编码序列上游，以增强目标基因表达的强度。
在一个实施方式中，其中所述酶编码基因和所述的调控元件整合入所述微生物的基因组 中。
在一个实施方式中，将包含所述述酶编码基因和所述的调控元件序列的质粒导入所述微生物中。
在一个实施例中，以整合入所述微生物的基因组的方法完成目标酶基因的导入、突变或敲除。
在一个实施例中，以同源重组的方法完成所述酶基因的导入、突变或敲除。
在一个实施例中，以两步同源重组的方法完成所述酶基因的导入、突变或敲除。
可采用本领域已知的同源重组系统，如大肠杆菌RecA重组系统，Red重组系统进行同源重组以实现目标基因的导入、突变或敲除。
以两步同源重组的方法导入、突变或敲除目标基因包括如下步骤(以大肠杆菌为例)：
(1)DNA片段I的制备：以pXZ-CS质粒(Tan,et al.,Appl Environ Microbiol,2013,79:4838-4844)DNA为模板，使用扩增引物1扩增出DNA片段I，用于第一步同源重组；
(2)第一步同源重组：将pKD46质粒(Datsenko and Wanner 2000,Proc Natl Acad Sci USA 97:6640-6645)转化至大肠杆菌，然后将DNA片段I转至pKD46的大肠杆菌，使用检测引物1验证转化的菌并挑选菌落；
(3)DNA片段II的制备：以出发大肠杆菌为模板，用扩增引物2扩增出DNA片段II。DNA片段II用于第二次同源重组。
(4)第二步同源重组：将DNA片段II转化至步骤(2)挑选获得的菌落；使用检测引物2验证转化的菌并挑选菌落。
本发明的第二个方面，是提供了一种利用上述构建方法得到的用于生产L-缬氨酸的重组微生物，具体是一种重组大肠杆菌，其包含乙酰羟酸异构还原酶和/或氨基酸脱氢酶基因，
在一个实施方式中，采用大肠杆菌ATCC 8739作为出发菌株，通过基因同源重组实现胞内辅因子NADH供给和细胞生长的偶联，从而实现厌氧条件下细胞生长和L-缬氨酸生产的偶联(附图1)。
在一个实施方式中，利用上述构建方法得到的重组大肠杆菌，进一步经过代谢进化，经过例如50代、70代、80代、90代、100代、120代获得了高产L-缬氨酸的重组大肠杆菌。在一个实施方式中，经105代代谢进化获得了一株产L-缬氨酸的重组大肠杆菌，其于2020年3月6日保藏于中国微生物菌种保藏管理委员会普通微生物中心，该保藏单位位于北京市朝阳区北辰西路1号院3号，保藏号为：CGMCC 19458，分类命名为大肠埃希氏菌Escherichia coli。
本发明的第三方面，是上述方法获得的重组微生物在生产L-缬氨酸中的应用。
本发明的第四方面，是利用上述构建获得的重组微生物发酵生产L-缬氨酸的方法，包括： (1)发酵培养构建获得的重组微生物；(2)分离并收获L-缬氨酸。
在一个实施方式中，所述发酵培养为厌氧发酵培养。
在一个实施方式中，所述厌氧发酵包括如下步骤：
(1)种子培养：挑取平板上的克隆接种到种子培养基中，37℃，振荡培养，获得种子培养液；
(2)发酵培养：将种子培养液接种于发酵培养基，37℃，150rpm，发酵2～4天，得到发酵液。控制发酵罐的pH在7.0。培养过程不通任何气体。
其中种子培养基由以下成分组成(溶剂为水)：
葡萄糖20g/L，玉米浆干粉10g/L，KH 2PO 4 8.8g/L、(NH 4) 2SO 4 2.5g/L、MgSO 4·7H 2O 2g/L。
发酵培养基和种子培养基成分相同，区别仅在于葡萄糖浓度为50g/L。
本发明的有益效果：
(1)相对于之前的生产方法和菌株，本发明实现了一步法厌氧发酵生产L-缬氨酸，降低了生产成本、提高了转化率。
(2)本发明优选对重组微生物的基因组而非以质粒形式构建稳定遗传的L-缬氨酸生产菌株，不需要额外添加抗生素和诱导剂等物质，生产工艺稳定易操作。
(3)通过代谢进化方式，提高了重组微生物的L-缬氨酸的产量和转化率以及细胞耐受性。
生物材料保藏
本发明构建的重组大肠杆菌Sval065，分类命名为：大肠埃希氏菌(Escherichia coli)，生物材料已于2020年3月6日提交保藏，保藏单位：中国微生物菌种保藏管理委员会普通微生物中心，保藏地址为北京市朝阳区北辰西路1号院3号，电话：010-64807355，保藏编号为CGMCC No.19458。
附图说明
构成本申请的一部分的说明书附图用来提供对本发明的进一步理解，本发明的示意性实施例及其说明用于解释本发明，并不构成对本发明的不当限定。在附图中：
图1：L-缬氨酸合成途径
图2：高效液相色谱测定L-缬氨酸的标准品
图3：高效液相色谱测定Sval064菌株发酵液组分
图4：代谢进化发酵培养获得Sval065菌株
图5：高效液相色谱测定L-缬氨酸的标准品
图6：高效液相色谱测定Sval065菌株发酵液组分
具体实施方式
本发明通过下述实施例进一步阐明，但任何实施例或其组合不应当理解为对本发明的范围或实施方式的限制。本发明的范围由所附权利要求书限定，结合本说明书和本领域一般常识，本领域普通技术人员可以清楚地明白权利要求书所限定的范围。在不偏离本发明的精神和范围的前提下，本领域技术人员可以对本发明的技术方案进行任何修改或改变，这种修改和改变也包含在本发明的范围内。
下述实施例中所使用的实验方法如无特殊说明，均为常规方法。下述实施例中所用的材料、试剂等，如无特殊说明，均可从商业途径得到。
本研究中所构建的菌株和质粒详见表1，所用引物详见表2。
表1本发明所用的菌株和质粒
Figure PCTCN2020137780-appb-000001
Figure PCTCN2020137780-appb-000002
表2本发明所用的引物
Figure PCTCN2020137780-appb-000003
Figure PCTCN2020137780-appb-000004
Figure PCTCN2020137780-appb-000005
Figure PCTCN2020137780-appb-000006
实施例1：ATCC 8739菌株中甲基乙二醛合酶编码基因mgsA的敲除
从大肠杆菌ATCC 8739出发，采用两步同源重组的方法敲除甲基乙二醛合酶编码基因 mgsA，具体步骤如下：
第一步，以pXZ-CS质粒DNA为模板，使用引物mgsA-cs-up/mgsA-cs-down扩增出2719bp的DNA片段I，用于第一步同源重组。
扩增体系为：Phusion 5X缓冲液(NewEngland Biolabs)10μl、dNTP(每种dNTP各10mM)1μl、DNA模板20ng、引物(10μM)各2μl、Phusion High-Fidelity DNA聚合酶(2.5U/μl)0.5μl、蒸馏水33.5μl，总体积为50μl。
扩增条件为：98℃预变性2分钟(1个循环)；98℃变性10秒、56℃退火10秒、72℃延伸2分钟(30个循环)；72℃延伸10分钟(1个循环)。
将上述DNA片段I用于第一次同源重组：首先将pKD46质粒-(购买于美国耶鲁大学CGSC大肠杆菌保藏中心，CGSC#7739)通过电转化法转化至大肠杆菌ATCC 8739，然后将DNA片段I电转至带有pKD46的大肠杆菌ATCC 8739。
电转条件为：首先准备带有pKD46质粒的大肠杆菌ATCC 8739的电转化感受态细胞；将50μl感受态细胞置于冰上，加入50ng DNA片段I，冰上放置2分钟，转移至0.2cm的Bio-Rad电击杯。使用MicroPulser(Bio-Rad公司)电穿孔仪，电击参数为电压2.5kv。电击后迅速将1ml LB培养基转移至电击杯中，吹打5次后转移至试管中，75rpm，30℃孵育2小时。取200μl菌液涂在含有氨苄霉素(终浓度为100μg/ml)和氯霉素(终浓度为34μg/ml)的LB平板上，30℃过夜培养后，挑选单菌落进行PCR验证，所用引物XZ-mgsA-up/XZ-mgsA-down，正确的菌落扩增产物为3646bp的片段，挑选一个正确的单菌落，命名为Sval001。
第二步，以野生型大肠杆菌ATCC 8739的基因组DNA为模板，用引物XZ-mgsA-up/mgsA-del-down扩增出566bp的DNA片段II。DNA片段II用于第二次同源重组。扩增条件和体系同第一步中所述。将DNA片段II电转至菌株Sval001。
电转条件为：首先准备带有pKD46质粒的Sval001的电转化感受态细胞；将50μl感受态细胞置于冰上，加入50ng DNA片段II，冰上放置2分钟，转移至0.2cm的Bio-Rad电击杯。使用MicroPulser(Bio-Rad公司)电穿孔仪，电击参数为电压2.5kv。电击后迅速将1ml LB培养基转移至电击杯中，吹打5次后转移至试管中，75转，30℃孵育4小时。将菌液转移至含有10％蔗糖的没有氯化钠的LB液体培养基(250ml烧瓶中装50ml培养基)，培养24小时后在含有6％蔗糖的没有氯化钠的LB固体培养基上划线培养。经过PCR验证，所用引物为XZ-mgsA-up/mgsA-del-down，正确的菌落扩增产物为1027bp的片段，挑选一个正确的单菌落，将其命名为Sval002。
实施例2：乳酸脱氢酶编码基因ldhA的敲除
从Sval002出发，通过两步同源重组的方法敲除乳酸脱氢酶编码基因ldhA，具体步骤如下：
第一步，以pXZ-CS质粒DNA为模板，使用引物ldhA-cs-up/ldhA-cs-dwon扩增出2719bp的DNA片段I，用于第一步同源重组。扩增体系和扩增条件与实施例1中所述一致。将DNA 片段I电转至Sval002。
将DNA片段I用于第一次同源重组：首先将pKD46质粒通过电转化法转化至大肠杆菌Sval002，然后将DNA片段I电转至带有pKD46的大肠杆菌Sval002。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第一步方法一致。取200μl菌液涂在含有氨苄霉素(终浓度为100μg/ml)和氯霉素(终浓度为34μg/ml)的LB平板上，30℃过夜培养后，挑选单菌落进行PCR验证，使用引物XZ-ldhA-up/XZ-ldhA-down进行验证，正确的PCR产物应该3448bp，挑选一个正确的单菌落，命名为Sval003。
第二步，以野生型大肠杆菌ATCC 8739的DNA为模板，用引物XZ-ldhA-up/ldhA-del-down扩增出476bp的DNA片段II。DNA片段II用于第二次同源重组。将DNA片段II电转至菌株Sval003。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第二步方法一致。菌落PCR对克隆进行验证，所用引物为XZ-ldhA-up/XZ-ldhA-down，正确的菌落扩增产物为829bp的片段，挑选一个正确的单菌落，将其命名为Sval004。
实施例3：磷酸乙酰转移酶编码基因pta和乙酸激酶编码基因ackA的敲除
从Sval004出发，通过两步同源重组的方法敲除磷酸乙酰转移酶编码基因pta和乙酸激酶编码基因ackA，具体步骤如下：
第一步，以pXZ-CS质粒DNA为模板，使用引物ackA-cs-up/pta-cs-down扩增出2719bp的DNA片段I，用于第一步同源重组。扩增体系和扩增条件与实施例1中所述一致。将DNA片段I电转至Sval004。
将DNA片段I用于第一次同源重组：首先将pKD46质粒通过电转化法转化至大肠杆菌Sval004，然后将DNA片段I电转至带有pKD46的大肠杆菌Sval004。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第一步方法一致。取200μl菌液涂在含有氨苄霉素(终浓度为100μg/ml)和氯霉素(终浓度为34μg/ml)的LB平板上，30℃过夜培养后，挑选单菌落进行PCR验证，使用引物XZ-ackA-up/XZ-pta-down进行验证，正确的PCR产物应该3351bp，挑选一个正确的单菌落，命名为Sval005。
第二步，以野生型大肠杆菌ATCC 8739的DNA为模板，用引物XZ-ackA-up/ackA-del-down扩增出371bp的DNA片段II。DNA片段II用于第二次同源重组。将DNA片段II电转至菌株Sval005。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第二步方法一致。菌落PCR对克隆进行验证，所用引物为XZ-ackA-up/XZ-pta-down，正确的菌落扩增产物为732bp的片段，挑选一个正确的单菌落，将其命名为Sval006。
实施例4：丙酸激酶编码基因tdcD和甲酸乙酰转移酶编码基因tdcE的敲除
从Sval006出发，通过两步同源重组的方法敲除丙酸激酶编码基因tdcD和甲酸乙酰转移酶编码基因tdcE，具体步骤如下：
第一步，以pXZ-CS质粒DNA为模板，使用引物tdcDE-cs-up/tdcDE-cs-down扩增出2719bp的DNA片段I，用于第一步同源重组。扩增体系和扩增条件与实施例1中所述一致。将DNA片段I电转至Sval006。
将DNA片段I用于第一次同源重组：首先将pKD46质粒通过电转化法转化至大肠杆菌Sval006，然后将DNA片段I电转至带有pKD46的大肠杆菌Sval006。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第一步方法一致。取200μl菌液涂在含有氨苄霉素(终浓度为100μg/ml)和氯霉素(终浓度为34μg/ml)的LB平板上，30℃过夜培养后，挑选单菌落进行PCR验证，使用引物XZ-tdcDE-up/XZ-tdcDE-down进行验证，正确的PCR产物应该4380bp，挑选一个正确的单菌落，命名为Sval007。
第二步，以野生型大肠杆菌ATCC 8739的DNA为模板，用引物XZ-tdcDE-up/tdcDE-del-down扩增出895bp的DNA片段II。DNA片段II用于第二次同源重组。将DNA片段II电转至菌株Sval007。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第二步方法一致。菌落PCR对克隆进行验证，所用引物为XZ-tdcDE-up/XZ-tdcDE-down，正确的菌落扩增产物为1761bp的片段，挑选一个正确的单菌落，将其命名为Sval008。
实施例5：醇脱氢酶基因adhE的敲除
从Sval008出发，通过两步同源重组的方法敲除醇脱氢酶基因adhE，具体步骤包括：
第一步，以pXZ-CS质粒DNA为模板，使用引物adhE-cs-up/adhE-cs-down扩增出2719bp的DNA片段I，用于第一步同源重组。扩增体系和扩增条件与实施例1中所述一致。
将DNA片段I用于第一次同源重组：首先将pKD46质粒通过电转化法转化至大肠杆菌Sval008，然后将DNA片段I电转至带有pKD46的大肠杆菌Sval008。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第一步方法一致。取200μl菌液涂在含有氨苄霉素(终浓度为100μg/ml)和氯霉素(终浓度为34μg/ml)的LB平板上，30℃过夜培养后，挑选单菌落进行PCR验证，使用引物XZ-adhE-up/XZ-adhE-down进行验证，正确的PCR产物应该3167bp，挑选一个正确的单菌落，命名为Sval009。
第二步，以野生型大肠杆菌ATCC 8739的DNA为模板，用引物XZ-adhE-up/adhE-del-down扩增出271bp的DNA片段II。DNA片段II用于第二次同源重组。将DNA片段II电转至菌株Sval009。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第二步方法一致。菌落PCR对克隆进行验证，所用引物为XZ-adhE-up/XZ-adhE-down，正确的菌落扩增产物为548bp的片段，挑选一个正确的单菌落，将其命名为Sval010。
实施例6：乙酰羟基酸还原异构酶编码基因ilvC在甲基乙二醛合酶编码基因mgsA位点的整合
从Sval010出发，通过两步同源重组的方法将来自大肠杆菌的乙酰羟基酸还原异构酶编码基因ilvC整合到甲基乙二醛合酶编码基因mgsA位点，具体步骤包括：
第一步，在Sval010菌株中mgsA位点整合cat-sacB片段，cat-sacB片段的PCR、整合、验证同实施例1中mgsA基因敲除的第一步完全一致，获得的克隆命名为Sval011。
第二步，以野生型大肠杆菌ATCC 8739的DNA为模板，用引物mgsA-ilvC-up/mgsA-ilvC-down扩增出1576bp的DNA片段II。DNA片段II用于第二次同源重组。将DNA片段II电转至菌株Sval011。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第二步方法一致。菌落PCR对克隆进行验证，所用引物为XZ-mgsA-up/XZ-mgsA-down，正确的菌落扩增产物为2503bp的片段，挑选一个正确的单菌落，将其命名为Sval012。
实施例7：乙酰羟基酸还原异构酶编码基因ilvC的调控
从Sval012出发，使用人工调控元件调控整合在甲基乙二醛合酶编码基因mgsA位点的乙酰羟基酸还原异构酶编码基因ilvC的表达，具体步骤如下：
第一步，以pXZ-CS质粒DNA为模板，使用引物mgsA-Pcs-up/mgsA-Pcs-down扩增出2719bp的DNA片段I，用于第一步同源重组。扩增体系和扩增条件与实施例1中所述一致。将DNA片段I电转至Sval012。
将DNA片段I用于第一次同源重组：首先将pKD46质粒通过电转化法转化至大肠杆菌Sval012，然后将DNA片段I电转至带有pKD46的大肠杆菌Sval012。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第一步方法一致。取200μl菌液涂在含有氨苄霉素(终浓度为100μg/ml)和氯霉素(终浓度为34μg/ml)的LB平板上，30℃过夜培养后，挑选单菌落进行PCR验证，使用引物XZ-mgsA-up/ilvC-YZ347-down进行验证，正确的PCR产物应该3482bp，挑选一个正确的单菌落，命名为Sval013。
第二步，以M1-46(Lu,et al.,Appl Microbiol Biotechnol,2012,93:2455-2462)的基因组DNA为模板，用引物mgsA-P46-up/ilvC-P46-down扩增出188bp的DNA片段II。DNA片段II用于第二次同源重组。将DNA片段II电转至菌株Sval013。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第二步方法一致。菌落PCR对克隆进行验证，所用引物为XZ-mgsA-up/ilvC-YZ347-down，正确的菌落扩增产物为951bp的片段，挑选一个正确的单菌落，将其命名为Sval014。
实施例8：二羟酸脱水酶编码基因ilvD的整合
从Sval014出发，通过两步同源重组的方法将来自大肠杆菌的二羟酸脱水酶编码基因ilvD 整合到丙酮酸甲酸裂解酶编码基因pflB位点并替换掉pflB基因，即在整合ilvD的同时敲除pflB基因，具体步骤如下：
第一步，以pXZ-CS质粒DNA为模板，使用引物pflB-CS-up/pflB-CS-down扩增出2719bp的DNA片段I，用于第一步同源重组。扩增体系和扩增条件与实施例1中所述一致。将DNA片段I电转至Sval014。
将DNA片段I用于第一次同源重组：首先将pKD46质粒通过电转化法转化至大肠杆菌Sval014，然后将DNA片段I电转至带有pKD46的大肠杆菌Sval014。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第一步方法一致。取200μl菌液涂在含有氨苄霉素(终浓度为100μg/ml)和氯霉素(终浓度为34μg/ml)的LB平板上，30℃过夜培养后，挑选单菌落进行PCR验证，使用引物XZ-pflB-up600/XZ-pflB-down进行验证，正确的PCR产物应该3675bp，挑选一个正确的单菌落，命名为Sval015。
第二步，以大肠杆菌MG1655(来自ATCC，编号700926)的基因组DNA为模板，用引物pflB-ilvD-up/pflB-ilvD-down扩增出1951bp的DNA片段II。DNA片段II用于第二次同源重组。将DNA片段II电转至菌株Sval015。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第二步方法一致。菌落PCR对克隆进行验证，所用引物为XZ-pflB-up600/XZ-pflB-down，正确的菌落扩增产物为2907bp的片段，挑选一个正确的单菌落，将其命名为Sval016。
实施例9：二羟酸脱水酶编码基因ilvD的表达调控
从Sval016出发，使用人工调控元件调控整合在丙酮酸甲酸裂解酶编码基因pflB位点的二羟酸脱水酶编码基因ilvD的表达，具体步骤如下：
第一步，以pXZ-CS质粒DNA为模板，使用引物pflB-Pcs-up/pflB-Pcs-down扩增出2719bp的DNA片段I，用于第一步同源重组。扩增体系和扩增条件与实施例1中所述一致。将DNA片段I电转至Sval016。
将DNA片段I用于第一次同源重组：首先将pKD46质粒通过电转化法转化至大肠杆菌Sval016，然后将DNA片段I电转至带有pKD46的大肠杆菌Sval016。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第一步方法一致。取200μl菌液涂在含有氨苄霉素(终浓度为100μg/ml)和氯霉素(终浓度为34μg/ml)的LB平板上，30℃过夜培养后，挑选单菌落进行PCR验证，使用引物XZ-pflB-up600/ilvD-YZ496-down进行验证，正确的PCR产物应该3756bp，挑选一个正确的单菌落，命名为Sval017。
第二步，以M1-93(Lu,et al.,Appl Microbiol Biotechnol,2012,93:2455-2462)的基因组DNA为模板，用引物pflB-Pro-up/ilvD-Pro-down扩增出189bp的DNA片段II。DNA片段II用于第二次同源重组。将DNA片段II电转至菌株Sval017。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第二步方法一致。菌落PCR对 克隆进行验证，所用引物为XZ-pflB-up600/ilvD-YZ496-down，正确的菌落扩增产物为1226bp的片段，挑选一个正确的单菌落，将其命名为Sval018。
实施例10：乙酰乳酸合成酶基因ilvBN的调控
使用人工调控元件M1-93通过两步同源重组的方法调控乙酰乳酸合成酶基因ilvBN的表达，具体步骤如下：
第一步，以pXZ-CS质粒DNA为模板，使用引物ilvB pro-catup/ilvB pro-catdown扩增出2719bp的DNA片段I，用于第一步同源重组。扩增体系和扩增条件与实施例1中所述一致。
将DNA片段I用于第一次同源重组：首先将pKD46质粒通过电转化法转化至大肠杆菌Sval018，然后将DNA片段I电转至带有pKD46的大肠杆菌Sval018。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第一步方法一致。取200μl菌液涂在含有氨苄霉素(终浓度为100μg/ml)和氯霉素(终浓度为34μg/ml)的LB平板上，30℃过夜培养后，挑选单菌落进行PCR验证，使用引物ilvB pro-YZup/ilvB pro-YZdown进行验证，正确的PCR产物应该2996bp，挑选一个正确的单菌落，命名为Sval019。
第二步，以M1-93(Lu,et al.,Appl Microbiol Biotechnol,2012,93:2455-2462)的基因组DNA为模板，用引物ilvB pro-up/ilvB pro-down扩增出188bp的DNA片段II。DNA片段II用于第二次同源重组。将DNA片段II电转至菌株Sval019。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第二步方法一致。菌落PCR对克隆进行验证，所用引物为ilvB pro-YZup/ilvB pro-YZdown，正确的菌落扩增产物为465bp的片段，挑选一个正确的单菌落，将其命名为Sval020。
实施例11：乙酰乳酸合成酶基因ilvGM的调控
使用人工调控元件M1-93通过两步同源重组的方法调控乙酰乳酸合成酶基因ilvGM的表达，具体步骤如下：
第一步，以pXZ-CS质粒DNA为模板，使用引物ilvG pro-catup/ilvG pro-catdown扩增出2719bp的DNA片段I，用于第一步同源重组。扩增体系和扩增条件与实施例1中所述一致。
将DNA片段I用于第一次同源重组：首先将pKD46质粒通过电转化法转化至大肠杆菌Sval020，然后将DNA片段I电转至带有pKD46的大肠杆菌Sval020。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第一步方法一致。取200μl菌液涂在含有氨苄霉素(终浓度为100μg/ml)和氯霉素(终浓度为34μg/ml)的LB平板上，30℃过夜培养后，挑选单菌落进行PCR验证，使用引物ilvG pro-YZup/ilvG p-YZdown进行验证，正确的PCR产物应该2993bp，挑选一个正确的单菌落，命名为Sval021。
第二步，以M1-93(Lu,et al.,Appl Microbiol Biotechnol,2012,93:2455-2462)的基因组DNA 质粒DNA为模板，用引物ilvG pro-up/ilvG pro-down扩增出188bp的DNA片段II。DNA片段II用于第二次同源重组。将DNA片段II电转至菌株Sval021。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第二步方法一致。菌落PCR对克隆进行验证，所用引物为ilvG pro-YZup/ilvG p-YZdown，正确的菌落扩增产物为462bp的片段，挑选一个正确的单菌落，将其命名为Sval022。
实施例12：乙酰乳酸合成酶基因ilvH的突变
通过两步同源重组的方法在ilvH基因中引入突变解除L-缬氨酸的反馈抑制，具体步骤如下：
第一步，以pXZ-CS质粒DNA为模板，使用引物ilvH*-cat-up/ilvH*-cat-down扩增出2719bp的DNA片段I，用于第一步同源重组。扩增体系和扩增条件与实施例1中所述一致。
将DNA片段I用于第一次同源重组：首先将pKD46质粒通过电转化法转化至大肠杆菌Sval022，然后将DNA片段I电转至带有pKD46的大肠杆菌Sval022。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第一步方法一致。取200μl菌液涂在含有氨苄霉素(终浓度为100μg/ml)和氯霉素(终浓度为34μg/ml)的LB平板上，30℃过夜培养后，挑选单菌落进行PCR验证，使用引物ilvH*-mutYZ-up/ilvH*-mut-down进行验证，正确的PCR产物应该3165bp，挑选一个正确的单菌落，命名为Sval023。
第二步，以野生型大肠杆菌ATCC 8739的DNA为模板，用引物ilvH*-mut-up/ilvH*-mut-down扩增出467bp的DNA片段II。DNA片段II用于第二次同源重组。将DNA片段II电转至菌株Sval023。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第二步方法一致。菌落PCR对克隆进行验证，所用引物为ilvH*-mutYZ-up/ilvH*-mut-down，正确的菌落扩增产物为619bp的片段，挑选一个正确的单菌落，将其命名为Sval024。
实施例13：使用重组菌株Sval024发酵生产L-缬氨酸
种子培养基由以下成分组成(溶剂为水)：
葡萄糖20g/L，玉米浆干粉10g/L，KH 2PO 4 8.8g/L、(NH 4) 2SO 4 2.5g/L、MgSO 4·7H 2O 2g/L。
发酵培养基大部分和种子培养基相同，区别仅在于葡萄糖浓度为50g/L。
Sval024的厌氧发酵包括以下步骤：
(1)种子培养：将LB平板上新鲜的克隆接种到含有4ml种子培养基的试管中，37℃，250rpm振荡培养过夜。然后，按照2％(V/V)的接种量将培养物转接到含有30ml种子培养基的250ml三角瓶中，在37℃，250rpm振荡培养12小时得到种子培养液用于发酵培养基接种。
(2)发酵培养：500ml厌氧罐中发酵培养基体积为250ml，将种子培养液按照终浓度 OD550＝0.1的接种量接种于发酵培养基，37℃，150rpm，发酵4天，得到发酵液。中和剂为5M氨水，使发酵罐的pH控制在7.0。培养过程中不通任何气体。
分析方法：使用安捷伦(Agilent-1260)高效液相色谱仪对发酵4天的发酵液中的组分进行测定。发酵液中的葡萄糖和有机酸浓度测定采用伯乐(Biorad)公司的Aminex HPX–87H有机酸分析柱。氨基酸测定使用Sielc氨基酸分析柱primesep 100 250×4.6mm。
结果发现：Sval024菌株在厌氧条件下发酵4天，能够生产1.3g/L的L-缬氨酸(出现与图2对应位置的L-缬氨酸峰)，糖酸转化率0.31mol/mol。
实施例14：亮氨酸脱氢酶编码基因leuDH的克隆与整合
leuDH基因是根据文献报道(Ohshima,T.et.al,Properties of crystalline leucine dehydrogenase from Bacillus sphaericus.The Journal of biological chemistry 253,5719-5725(1978))的来自Lysinibacillus sphaericus IFO 3525菌株的leuDH序列并经过密码子优化(优化序列为序列69)后通过全基因合成获得，合成时在leuDH基因前加上M1-93人工调控元件用于启动leuDH基因的表达，插入pUC57载体，构建获得质粒pUC57-M1-93-leuDH(南京金斯瑞生物科技有限公司完成基因合成和载体构建)。将M1-93人工调控元件和leuDH基因一起通过来两步同源重组的方法整合到Sval024菌株中富马酸还原酶编码基因frd位点并替换掉frd基因，即在整合leuDH的同时敲除frd基因。具体步骤包括：
第一步，以pXZ-CS质粒DNA为模板，使用引物frd-cs-up/frd-cs-down扩增出2719bp的DNA片段I，用于第一步同源重组。扩增体系和扩增条件与实施例1中所述一致。
将DNA片段I用于第一次同源重组：首先将pKD46质粒通过电转化法转化至大肠杆菌Sval024，然后将DNA片段I电转至带有pKD46的大肠杆菌Sval024。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第一步方法一致。取200μl菌液涂在含有氨苄霉素(终浓度为100μg/ml)和氯霉素(终浓度为34μg/ml)的LB平板上，30℃过夜培养后，挑选单菌落进行PCR验证，使用引物XZ-frd-up/XZ-frd-down进行验证，正确的PCR产物应该3493bp，挑选一个正确的单菌落，命名为Sval025。
第二步，以pUC57-M1-93-leuDH质粒DNA为模板，用引物frd-M93-up/frd-leuDH-down扩增出1283bp的DNA片段II。DNA片段II用于第二次同源重组。将DNA片段II电转至菌株Sval025。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第二步方法一致。菌落PCR对克隆进行验证，所用引物为XZ-frd-up/XZ-frd-down，正确的菌落扩增产物为2057bp的片段，挑选一个正确的单菌落，将其命名为Sval026。
实施例15：使用重组菌株Sval026发酵生产L-缬氨酸
种子培养基和发酵培养基的组成和配制同实施例13中所述相同。
发酵在500mL的发酵罐中进行，发酵过程和分析过程同实施例13中所述Sval024的发酵 过程和分析过程一致。
结果发现：Sval026菌株在厌氧条件下发酵4天，能够生产1.8g/L的L-缬氨酸(出现与图2对应位置的L-缬氨酸峰)，糖酸转化率0.56mol/mol。
实施例16：NADH依赖性乙酰羟基酸还原异构酶编码基因在醇脱氢酶基因adhE位点的整合
乙酰羟基酸还原异构酶编码基因kari是根据文献报道(Brinkmann-Chen,S.,Cahn,J.K.B.&Arnold,F.H.Uncovering rare NADH-preferring ketol-acid reductoisomerases.Metab Eng 26,17-22,doi:10.1016/j.ymben.2014.08.003(2014).)的来自Thermacetogenium phaeum菌株的kari序列并经过密码子优化(优化序列参见序列70)后通过全基因合成获得，合成时在kari基因前加上RBS5人工调控元件用于启动kari基因的表达，插入pUC57载体，构建获得质粒pUC57-RBS5-kari(南京金斯瑞生物科技有限公司完成基因合成和载体构建)。将RBS5人工调控元件和kari基因一起通过来两步同源重组的方法整合到Sval026菌株中醇脱氢酶编码基因adhE位点。具体步骤包括：
第一步，将cat-sacB基因整合Sval026中adhE基因位点，片段的获得和纯化、第一步同源重组的整合、验证同实施例5中adhE基因敲除第一步同源重组所用片段和方法完全一致，获得的克隆命名为Sval061(表1)。
第二步，以pUC57-RBS5-kari质粒DNA为模板，用引物adhE-RBS5-up/adhE-kari-down扩增出1188bp的DNA片段II。DNA片段II用于第二次同源重组。将DNA片段II电转至菌株Sval061。
电转条件和步骤同实施例1中所述用于mgsA基因敲除的第二步方法一致。菌落PCR对克隆进行验证，所用引物为XZ-adhE-up/XZ-adhE-down，正确的菌落扩增产物为1636bp的片段，挑选一个正确的单菌落，将其命名为Sval062。
实施例17：mgsA位点NADPH依赖性乙酰羟基酸还原异构酶编码基因的敲除
通过两步同源重组的方法敲除整合在甲基乙二醛合酶编码基因mgsA位点的NADPH依赖性乙酰羟基酸还原异构酶编码基因ilvC，具体步骤如下：
第一步，将cat-sacB基因整合到mgsA位点替代ilvC基因，片段的获得和纯化、第一步同源重组的整合、验证同实施例1中mgsA敲除第一步同源重组所用片段和方法完全一致，获得的克隆命名为Sval063(表1)。
第二步，使用mgsA敲除的片段替代cat-sacB片段，获得mgsA基因及ilvC基因敲除的菌株，片段的获得和纯化、第二步同源重组的整合、验证同实施例1中mgsA敲除第二步同源重组所用片段和方法完全一致，获得的克隆命名为Sval064。
实施例18：使用重组菌株Sval064发酵生产L-缬氨酸
种子培养基和发酵培养基的组成和配制同实施例13中所述相同。
发酵在500mL的发酵罐中进行，发酵过程和分析过程同实施例13中所述Sval024的发酵过程和分析过程一致。
结果发现：
Sval064菌株在厌氧条件下发酵4天，能够生产2.0g/L的L-缬氨酸(出现与图2对应位置的L-缬氨酸峰)，糖酸转化率0.80mol/mol(图3)。
实施例19：重组菌株Sval065的构建
从Sval064开始，通过进化代谢同步提高细胞生长和L-缬氨酸的生产能力。
进化代谢过程使用500ml的发酵罐，发酵培养基为250ml。使用5M氨水为中和剂，使发酵罐的pH控制在7.0。进化代谢所用的发酵培养基组成和配制同实施例16中发酵培养基所述。每24小时，将发酵液转接到新的发酵罐中，使初始OD550达0.1，经过105代进化，获得菌株Sval065(图4)。Sval065菌株以保藏号CGMCC 19458保藏于中国普通微生物菌种保藏管理中心(CGMCC)。
实施例20：重组菌株Sval065在500mL发酵罐中发酵生产L-缬氨酸
种子培养基的组成和配制同实施例13中所述相同。
发酵在500mL的发酵罐中进行，发酵培养基为250ml。发酵培养基基本上和种子培养基相同，区别是葡萄糖浓度为100g/L，使用的中和剂为5M氨水，使发酵罐的pH控制在7.0。
结果发现：Sval065发酵48小时后，L-缬氨酸产量达45g/L，产率达0.9mol/mol，无杂酸等杂质生成。
实施例21：重组菌株Sval065在5L发酵罐中发酵生产L-缬氨酸
种子培养基的组成和配制、分析方法同实施例13中所述相同。发酵培养基基本上和种子培养基相同，区别仅在于葡萄糖浓度为140g/L。
发酵在5L发酵罐(上海保兴，BIOTECH-5BG)中厌氧进行，包括以下步骤：
(1)种子培养：500ml三角瓶中种子培养基为150ml，115℃灭菌15min。冷却后将重组大肠杆菌Sval045按照1％(V/V)的接种量接种于种子培养基，在37℃和100rpm的条件下培养12小时得到种子液，用于发酵培养基接种。
(2)发酵培养：5L中发酵培养基体积为3L，115℃灭菌25min。将种子液按照终浓度OD550＝0.2的接种量接种于发酵培养基，37℃厌氧培养3天，搅拌转速200rpm，得到发酵液。发酵液为发酵罐内所有物质。培养过程没有通任何气体。
结果发现：Sval065发酵48小时后，L-缬氨酸产量达83g/L，产率达0.92mol/mol(0.6g/g)，无杂酸等杂质生成(图5-6)。

Claims (10)

  1. 一种生产L-缬氨酸的重组微生物的构建方法，其特征在于：向微生物中导入乙酰羟酸异构还原酶基因和/或氨基酸脱氢酶基因，使得所述乙酰羟酸异构还原酶基因和/或氨基酸脱氢酶的酶活性增强；
    优选地，所述乙酰羟酸异构还原酶基因和/或氨基酸脱氢酶基因是NADH依赖型；
    优选地，所述乙酰羟酸异构还原酶基因是ilvC或KARI；所述氨基酸脱氢酶基因是亮氨酸脱氢酶基因；
    更优选地，所述乙酰羟酸异构还原酶基因是KARI，所述氨基酸脱氢酶基因是leuDH。
  2. 根据权利要求1所述的构建方法，其特征在于：还包括对权利要求1所述的重组微生物进行以下(1)-(7)中的一种或几种改造：
    (1)敲除mgsA基因；
    (2)敲除ldhA基因；
    (3)敲除pta和/或ackA基因；
    (4)敲除tdcD和/或tdcE基因；
    (5)敲除adhE基因；
    (6)敲除frd和/或pflB基因；
    (7)增强乙酰乳酸合成酶AHAS和/或二羟酸脱水酶ilvD的活性；
    优选地，AHAS为ilvBN或ilvGM或ilvIH；任选地，所述ilvIHAHAS的活性通过解除缬氨酸对所述ilvH的反馈抑制得到增强，优选的，通过突变ilvH基因得到增强；
    优选地，选择上述第(7)项进行改造；
    优选地，选择上述第(7)和第(2)项进行改造；
    优选地，选择上述第(7)和第(6)项进行改造；
    优选地，选择上述第(7)项、第(2)项和第(5)项进行改造；
    优选地，选择上述第(7)项、第(1)项、第(3)-(6)项进行改造；
    优选地，选择上述第(1)-(7)项进行改造；
    优选地，采用突变ilvH基因的方式解除缬氨酸对ilvIH的反馈抑制；
    优选地，以ilvD基因替换微生物本身的pflB基因的方式实现第(6)项；
    优选地，以leuDH基因替换微生物本身的frd基因的方式实现第(6)项；
    优选地，以KARI基因替换微生物本身的adhE基因的方式实现第(5)项；
    优选地，以ilvC基因替换微生物本身的mgsA基因的方式实现第(1)项，且ilvC在导入后任选地可再次敲除。
  3. 根据权利要求1或2所述的构建方法，其特征在于，所述微生物为大肠杆菌；更优选的，所述微生物为大肠杆菌ATCC 8739。
  4. 根据权利要求1-3中任一项所述的构建方法，其特征在于，使用至少一个调控元件增强所述酶的基因的活性；
    优选地，所述调控元件选自M1-46人工调控元件、M1-93人工调控元件或RBS5人工调控元件；
    优选地，所述M1-46人工调控元件调控ilvC基因；
    所述M1-93人工调控元件调控ilvD、leuDH、ilvBN和ilvGM基因；
    所述RBS5人工调控元件调控KARI基因。
  5. 根据权利要求1-4中任一项所述的构建方法，其特征在于，其中所述酶编码基因的一个或多个拷贝和所述调控元件整合入所述微生物的基因组中，或者将包含所述酶编码基因的质粒导入所述微生物中；
    优选地，以整合入所述微生物的基因组的方法完成所述酶基因的导入、突变、敲除或调控；
    优选地，以同源重组的方法完成所述酶基因的导入、突变、敲除或调控；
    优选地，以两步同源重组的方法完成所述酶基因的导入、突变、敲除或调控。
  6. 利用权利要求1-5中任一所述的构建方法得到的重组微生物。
  7. 一种获得高产L-缬氨酸的重组微生物的方法，其特征在于，在权利要求5所述的重组微生物的基础上，经过代谢进化获得。
  8. 一种重组微生物，其保藏号为CGMCC 19458。
  9. 权利要求6或权利要求8所述的重组微生物在生产L-缬氨酸中的应用。
  10. 一种生产L-缬氨酸的方法，其特征在于，包括：(1)发酵培养权利要求6或8所述的重组微生物；(2)分离并收获L-缬氨酸；优选地，所述发酵培养为厌氧发酵培养。
PCT/CN2020/137780 2020-05-13 2020-12-18 生产l-缬氨酸的重组微生物及构建方法、应用 WO2021227500A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP20925003.4A EP3929297A4 (en) 2020-05-13 2020-12-18 RECOMBINANT MICROORGANISM FOR THE PRODUCTION OF L-VALINE, PROCESS FOR ITS PRODUCTION AND ITS USE
US17/603,008 US20230072835A1 (en) 2020-05-13 2020-12-18 Recombinant microorganism for producing L-valine, construction method and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010401422.5 2020-05-13
CN202010401422.5A CN113278655B (zh) 2020-05-13 2020-05-13 生产l-缬氨酸的重组微生物及构建方法、应用

Publications (1)

Publication Number Publication Date
WO2021227500A1 true WO2021227500A1 (zh) 2021-11-18

Family

ID=77275618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/137780 WO2021227500A1 (zh) 2020-05-13 2020-12-18 生产l-缬氨酸的重组微生物及构建方法、应用

Country Status (4)

Country Link
US (1) US20230072835A1 (zh)
EP (1) EP3929297A4 (zh)
CN (3) CN113278655B (zh)
WO (1) WO2021227500A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3943595A4 (en) * 2020-05-27 2022-10-12 Anhui Huaheng Biotechnology Co., Ltd. RECOMBINANT MICROORGANISM FOR THE PRODUCTION OF L-VALINE, PROCESS FOR ITS PRODUCTION AND ITS USE
EP3943594A4 (en) * 2020-05-27 2023-08-02 Anhui Huaheng Biotechnology Co., Ltd. RECOMBINANT MICROORGANISM FOR THE PRODUCTION OF L-VALINE, PROCESS FOR ITS PRODUCTION AND ITS USE

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116536237B (zh) * 2023-06-29 2023-11-10 北京中科伊品生物科技有限公司 改造的大肠杆菌及其在发酵生产l-缬氨酸中的应用
CN117844728B (zh) * 2024-03-04 2024-06-04 天津科技大学 一种l-缬氨酸生产菌株及其构建方法与应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737255B2 (en) 2000-01-26 2004-05-18 Ajinomoto Co., Inc. Mutant ilvH gene and method for producing L-valine
US20090163376A1 (en) * 2007-12-20 2009-06-25 E.I. Du Pont De Nemours And Company Ketol-acid reductoisomerase using nadh
WO2013009818A2 (en) * 2011-07-11 2013-01-17 Gevo, Inc. High-performance ketol-acid reductoisomerases
US20140017748A1 (en) * 2010-02-12 2014-01-16 Gevo, Inc. Modified alcohol dehydrogenases for the production of fuels and chemicals
CN103946370A (zh) * 2011-08-22 2014-07-23 公益财团法人地球环境产业技术研究机构 棒状细菌转化体和使用该转化体的缬氨酸的制造方法
CN104561074A (zh) * 2014-12-30 2015-04-29 福建师范大学 一株高产l-缬氨酸工程菌的构建及其应用
CN110607268A (zh) * 2019-10-24 2019-12-24 天津科技大学 一株高产l-缬氨酸的基因工程菌及发酵生产l-缬氨酸方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06277067A (ja) * 1993-03-26 1994-10-04 Mitsubishi Petrochem Co Ltd アセトヒドロキシ酸イソメロレダクターゼをコードする遺伝子ｄｎａ
CN1370234A (zh) * 1999-06-25 2002-09-18 Basf公司 编码参与内环境稳定和适应的蛋白质的谷氨酸棒杆菌基因
WO2008119009A2 (en) * 2007-03-27 2008-10-02 University Of Florida Research Foundation, Inc. Materials and methods for efficient alanine production
US20100143997A1 (en) * 2008-10-31 2010-06-10 Thomas Buelter Engineered microorganisms capable of producing target compounds under anaerobic conditions
CN102712912A (zh) * 2009-09-29 2012-10-03 布特马斯先进生物燃料有限责任公司 在乳酸菌中改善流向乙酰乳酸来源产物的流量
JP6133010B2 (ja) * 2011-09-16 2017-05-24 協和発酵バイオ株式会社 アミノ酸の製造法
CN108486082A (zh) * 2012-10-18 2018-09-04 中粮生物化学（安徽）股份有限公司 天冬氨酸激酶iii突变体及其宿主细胞和应用
CN104178443B (zh) * 2013-05-24 2017-04-12 中国科学院天津工业生物技术研究所 生产丁二酸的重组大肠杆菌及其应用
CN103642766B (zh) * 2013-07-02 2016-12-28 廊坊梅花生物技术开发有限公司 蛋白、dna分子、含有该dna的转化宿主及该转化宿主用于生产l‑缬氨酸的方法
US20190040417A1 (en) * 2016-02-09 2019-02-07 Kembiotix Llc Biological fermentation using dihydroxyacetone as a source of carbon
CN109306343A (zh) * 2017-07-26 2019-02-05 中国科学院微生物研究所 新型天冬氨酸脱氢酶及在天冬氨酸族氨基酸生产上的应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737255B2 (en) 2000-01-26 2004-05-18 Ajinomoto Co., Inc. Mutant ilvH gene and method for producing L-valine
US20090163376A1 (en) * 2007-12-20 2009-06-25 E.I. Du Pont De Nemours And Company Ketol-acid reductoisomerase using nadh
US20140017748A1 (en) * 2010-02-12 2014-01-16 Gevo, Inc. Modified alcohol dehydrogenases for the production of fuels and chemicals
WO2013009818A2 (en) * 2011-07-11 2013-01-17 Gevo, Inc. High-performance ketol-acid reductoisomerases
CN103946370A (zh) * 2011-08-22 2014-07-23 公益财团法人地球环境产业技术研究机构 棒状细菌转化体和使用该转化体的缬氨酸的制造方法
CN104561074A (zh) * 2014-12-30 2015-04-29 福建师范大学 一株高产l-缬氨酸工程菌的构建及其应用
CN110607268A (zh) * 2019-10-24 2019-12-24 天津科技大学 一株高产l-缬氨酸的基因工程菌及发酵生产l-缬氨酸方法

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BRINKMANN-CHEN, S.CAHN, JKBARNOLD, FH: "Uncovering rare NADH-preferring ketol-acid reductoisomerases", METAB ENG, vol. 26, 2014, pages 17 - 22
DATSENKOWANNER, PROC NATL ACAD SCI USA, vol. 97, 2000, pages 6640 - 6645
DE FELICE ET AL., JOURNAL OF BACTERIOLOGY, vol. 120, 1974, pages 1058 - 1067
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 253, 1978, pages 5719 - 5725
LU ET AL., APPL MICROBIOL BIOTECHNOL, vol. 93, 2012, pages 2455 - 2462
S. HASEGAWA, K. UEMATSU, Y. NATSUMA, M. SUDA, K. HIRAGA, T. JOJIMA, M. INUI, H. YUKAWA: "Improvement of the Redox Balance Increases L-Valine Production by Corynebacterium glutamicum under Oxygen Deprivation Conditions", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 78, no. 3, 1 February 2012 (2012-02-01), pages 865 - 875, XP055174358, ISSN: 00992240, DOI: 10.1128/AEM.07056-11 *
S. HASEGAWA, M. SUDA, K. UEMATSU, Y. NATSUMA, K. HIRAGA, T. JOJIMA, M. INUI, H. YUKAWA: "Engineering of Corynebacterium glutamicum for High-Yield L-Valine Production under Oxygen Deprivation Conditions", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 79, no. 4, 15 February 2013 (2013-02-15), pages 1250 - 1257, XP055174400, ISSN: 00992240, DOI: 10.1128/AEM.02806-12 *
SAVRASOVA EKATERINA A., STOYNOVA NATALIYA V.: "Application of leucine dehydrogenase Bcd from Bacillus subtilis for l-valine synthesis in Escherichia coli under microaerobic conditions", HELIYON, vol. 5, no. 4, 1 April 2019 (2019-04-01), GB , pages e01406, XP055866421, ISSN: 2405-8440, DOI: 10.1016/j.heliyon.2019.e01406 *
See also references of EP3929297A4
TAN ET AL., APPL ENVIRON MICROBIOL, vol. 79, 2013, pages 4838 - 4844
VYAZMENSKY, M ET AL., BIOCHEMISTRY, vol. 35, 1996, pages 10339 - 10346
ZENG, BANGDING ET AL.: "Effects of Brevibacterium Flavum with Directed Mutagenesis of ilvN and Co-Expression of ilvBNC Cluster on L-Valine Production", CIESC JOURNAL, vol. 67, no. 7, 31 July 2016 (2016-07-31), pages 2956 - 2962, XP055866423 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3943595A4 (en) * 2020-05-27 2022-10-12 Anhui Huaheng Biotechnology Co., Ltd. RECOMBINANT MICROORGANISM FOR THE PRODUCTION OF L-VALINE, PROCESS FOR ITS PRODUCTION AND ITS USE
EP3943594A4 (en) * 2020-05-27 2023-08-02 Anhui Huaheng Biotechnology Co., Ltd. RECOMBINANT MICROORGANISM FOR THE PRODUCTION OF L-VALINE, PROCESS FOR ITS PRODUCTION AND ITS USE

Also Published As

Publication number Publication date
CN114457123A (zh) 2022-05-10
EP3929297A4 (en) 2022-09-21
US20230072835A1 (en) 2023-03-09
EP3929297A1 (en) 2021-12-29
CN114457123B (zh) 2023-06-20
CN114457122A (zh) 2022-05-10
CN114457122B (zh) 2023-06-20
CN113278655A (zh) 2021-08-20
CN113278655B (zh) 2022-05-17

Similar Documents

Publication Publication Date Title
WO2021227500A1 (zh) 生产l-缬氨酸的重组微生物及构建方法、应用
WO2021238184A1 (zh) 生产l-缬氨酸的重组微生物、其构建方法及应用
US11802300B2 (en) Genetically engineered strain with high yield of L-valine and method for producing L-valine by fermentation
WO2021238183A1 (zh) 生产l-缬氨酸的重组微生物、其构建方法及应用
Zhang et al. Production of L-alanine by metabolically engineered Escherichia coli
JP7373661B2 (ja) Ｌ－アルギニンを生産する遺伝子組換え菌、その構築方法及び使用
ES2401339T3 (es) Materiales y métodos para producción eficiente de ácido láctico
WO2019237824A1 (zh) 一种生产酪醇及羟基酪醇的酵母及构建方法
WO2014121724A1 (zh) 5-氨基乙酰丙酸高产菌株及其制备方法和应用
WO2008119009A2 (en) Materials and methods for efficient alanine production
WO2022174597A1 (zh) 一种用于l-肌氨酸生产的基因工程菌及构建方法与应用
KR101483012B1 (ko) 재조합 대장균을 이용하여 3-히드록시프로피온산을 고수율로 생산하는 방법
JP2017514511A (ja) ショ糖におけるファインケミカルの改善された生産のための遺伝的改変微生物
WO2015003629A1 (zh) 生产d-乳酸的重组大肠杆菌及其应用
CN112592875B (zh) 一株高丝氨酸生产菌及其构建方法和应用
WO2006025477A1 (ja) 工業的に有用な微生物
WO2023246071A1 (zh) 一种mreC突变体及其在L-缬氨酸发酵生产中的应用
US11479795B2 (en) Genetically engineered bacterium for sarcosine production as well as construction method and application
JP4334565B2 (ja) 染色体内のｔｄｃＢＣ及びｐｃｋＡ遺伝子が不活性化された微生物及びこれを用いてＬ−トレオニンを製造する方法
RU2820627C1 (ru) Генно-инженерные бактерии для продуцирования l-аргинина и способ конструирования и применения генно-инженерных бактерий
CN117004547B (zh) 一种以葡萄糖为底物从头合成顺，顺-粘康酸的基因工程菌及其应用
US20150247174A1 (en) Engineering bacteria for producing dl-alanine and method for producing dl-alanine by using engineering bacteria
Brown Biosynthetic Pathway for the Production of Acetoin in Escherichia coli
CN118165905A (zh) 一株产l-丝氨酸的谷氨酸棒杆菌突变株的构建与应用
CN117946950A (zh) 一种新的生产2-羟基异戊酸的脱氢酶及2-羟基异戊酸工程菌的构建和应用

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2020925003

Country of ref document: EP

Effective date: 20210924

NENP Non-entry into the national phase

Ref country code: DE